European Neuropsychopharmacology

Finding a path through the forest of the GABA_A receptors
pp. 53-53(1)
Author: Barnard E.A.

G protein coupled receptors, allosteric modulators and psychiatry: The model of 5-HT moduline
pp. 53-54(2)
Author: Fillion G.

Challenge for early interventions: Onset, prodromal phase and early course of schizophrenia
pp. 54-55(2)
Authors: Hafner H.; an der Heiden W.; Loffler W.; Maurer K.

Some thoughts on the validity of the concept of panic disorder
pp. 57-57(1)
Author: Klein D.F.

Basic mechanisms of panic and depression: Are they separate?
pp. 57-58(2)
Author: Westenberg H.G.M.

Dysfunctional components of 5-HT neurotransmission in anxiety and depression
pp. 58-59(2)
Author: Deakin J.F.W.

Priorities of treatment in panic disorder
pp. 59-59(1)
Author: den Boer J.A.

Treating panic and depression in primary care
pp. 59-60(2)
Author: Wade A.

The course of addiction; An encounter of biology, psychology and medicine
pp. 60-61(2)
Authors: Gerrits M.A.E.; van Ree J.M.

Brain mechanisms involved in individual susceptibility to drugs of abuse
pp. 61-61(1)
Authors: Piazza P.V.; Deroche V.; Marinelli M.; Barrot M.; Rouge Pont F.; Le Moal M.

Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with behavioural sensitization
pp. 61-62(2)
Authors: Schoffelmeer A.N.M.; Vanderschuren L.J.M.I.; Mulder A.H.; De Vries T.J.

Drug craving in animals
pp. 62-63(2)
Author: Spanagel R.

Cerebral activations and cognitive loading in schizophrenia
pp. 63-63(1)
Authors: Artigest E.; Martinott J.L.; Salame P.; Attar-Levy D.; Paillere M.L.; Mallett L.; Verdys M.; Tzourio N.; Recasens C.

Neurocomputational models of cognitive dysfunctions in schizophrenia and therapeutic implications
pp. 63-64(2)
Author: Spitzer M.

A neurobiological perspective of schizophrenia derived from functional neuroimaging
pp. 64-65(2)
Author: Dolan R.J.

Animal models of cognitive dysfunction in schizophrenia
pp. 65-65(1)
Author: Robbins T.W.

Studies in vivo of the nitric oxide/cyclic GMP pathway in the brain
pp. 65-66(2)
Authors: Raiteri M.; Varnier G.; Fedele E.

Effects of NO on ionic channels
pp. 66-66(1)
Author: Bockaert J.

Modulation of striatal serotonin and metabolite levels by nitric oxide: An in vivo microdielysis study
pp. 66-67(2)
Authors: Trabace L.; Kendrick K.M.

Nitric oxide involvement in neurodegeneration
pp. 67-67(1)
Author: Garthwaite J.

Nitric oxide and memory
pp. 67-68(2)
Author: Kendrick K.M.

Treatment of bipolar depression
pp. 68-69(2)
Authors: Calabrese J.R.; Bowden C.L.; McElroy S.L.; Sachs G.S.; Suppes T.

The impact of long-term lithium prophylaxis on the course of bipolar disorder
pp. 69-69(1)
Author: Maj M.

Advances on prophylactics of bipolar disorder
pp. 69-70(2)
Author: Bowden C.

Clinical implications of comorbidity in bipolar disorder
pp. 70-70(1)
Authors: Cassano G.B.; Pini S.; Dell'Osso L.

Opiate substitution treatment combining opiate agonist treatment with appropriate psychosocial interventions and maintaining quality of care
pp. 70-71(2)
Authors: Farrell M.; Marsden J.; Finch E.; Gossop M.; Strang J.

The use of LAAM, a substitute opiate, at Taipas centre: Four years experience (May 1994-May 1998)
pp. 71-71(1)
Authors: Patricio L.D.; Costa A.; Duran D.

Methods to study prevention of relapse
pp. 71-72(2)
Author: O'Brien C.P.

Treatment of comorbidity
pp. 72-72(1)
Author: Fuchs W.J.

Diverse signalling through a single 5-HT receptor subtype
pp. 72-73(2)
Author: Pauwels P.J.

Control of the serotonergic activity and gene expression by 5-HT moduline
pp. 73-74(2)
Authors: Grimaldi B.; Sibella-Arguelles C.; Bonnin A.; Fillion M.-P.; Massot O.; Rousselle J.-C.; Prudhomme N.; Fillion G.

Control of the expression of genes related to serotonergic transmission: The tryptophane hydroxylase implication
pp. 74-74(1)
Author: Mallet J.

5-HT receptor knockout mice as models of psychiatric disorders
pp. 74-75(2)
Authors: Zhuang X.; Hen R.

Disorder of synaptic homeostasis in depression and its treatment
pp. 75-76(2)
Authors: Grahame-Smith D.G.; Zetterstrom T.S.C.; Pei Q.

Do anxious and depressive states share common genetic factors?
pp. 76-77(2)
Authors: Prescott C.A.; Kendler K.S.

Common risk factors in anxiety and depressive disorders
pp. 77-77(1)
Author: Wittchen H.-U.

Pharmacological approaches predicting antidepressant or anxiolytic activities: What is common and what is different
pp. 78-78(1)
Author: Olivier B.

The clinical interrelation between anxiety and mood disorders
pp. 78-79(2)
Author: Linden M.

Variability of placebo response in anxiety disorders
pp. 79-80(2)
Author: Buller R.

Investigator influence on drug-placebo differences in depression
pp. 80-80(1)
Authors: Sennef C.; Pinder R.M.; Reimitz P.E.; Niklson I.A.

Controlling the placebo response rates in depression
pp. 80-81(2)
Authors: Potter W.Z.; Demitrack M.A.; DeBrota D.J.; Faries D.; Herrera J.

Placebo-controlled trials in schizophrenia
pp. 81-81(1)
Authors: Storosum J.G.; Elferink A.; van Zwieten-Boot B.J.

D1-D3 receptor interplay in schizophrenia: An hypothesis
pp. 81-81(1)
Authors: Schwartz J.-C.; Diazt J.; Bordett R.; Griffon N.; Perachon S.; Pilon C.; Ridrayt S.; Sokoloff P.

Molecular genetic studies of dopamine and serotonin receptor genes in schizophrenia
pp. 82-82(1)
Author: Owen M.J.

Segregation and co-expression of D2 and D3 receptors in the brain of schizophrenic patients: Postmortem studies
pp. 82-83(2)
Authors: Joyce J.N.; Gurevich E.V.; Himes J.W.; Ryoo H.

Striatai and extrastriatal D2-dopamine receptor occupancy during haloperidol and ciozapine treatment
pp. 83-83(1)
Authors: Farde L.; Olsson H.; Talvik-Lotfi M.; Halldin C.

Cognitive deficits and cortical dopamine dysfunction in a primate model of schizophrenia
pp. 83-84(2)
Authors: Jentsch J.D.; Roth R.H.

Transcription factors in specification of peptidergic and aminergic transmitter systems during brain development: The ptx homeobox gene family
pp. 84-84(1)
Authors: Burbach J.P.H.; Smidt M.P.

Neuropepide Y and its receptors in brain diseases and after nerve injury
pp. 84-85(2)
Authors: Hokfelt T.; Broberger C.; Diez M.; Zhang X.; Kopp J.; Xu Z.-Q.; Landry M.; Bao L.

Substance P
pp. 85-85(1)
Author: Feighner J.P.

Neurotensin in schizophrenia and Parkinson's disease
pp. 86-86(1)
Author: O'Connor W.T.

What can we learn from CSF studies: The CRF database
pp. 86-87(2)
Author: Nemeroff C.B.

COMT inhibition and Parkinson's disease
pp. 87-88(2)
Authors: Dorflinger E.; Magni G.; Hoffmann F.

Novel strategies for the palliative treatment of Parkinson's disease
pp. 88-89(2)
Authors: Chase T.N.; Oh J.D.

The stimulation of deep cerebral structures in the treatment of Parkinson's disease
pp. 89-89(1)
Author: Damier P.

Basic neuronal mechanisms of sleep
pp. 89-90(2)
Author: Stetiade M.

The pharmacological treatment of narcolepsy
pp. 90-91(2)
Author: Billiard M.

Brain imaging of sleep
pp. 91-91(1)
Authors: Buchsbaum M.S.; Gillin J.C.; Win J.; Bunhey W.E.

Delta sleep dynamics in man
pp. 91-92(2)
Authors: Linkowski P.; Preud'homme X.

Melatonin: New advances in sleep research and treatment
pp. 92-92(1)
Author: Wirz-Justice A.

The longterm effects of obstetric complications on the adolescent and adult brain
pp. 92-93(2)
Authors: Murray R.M.; Fearon P.; Rifkin L.; Rushe T.

Long-term behavioural disorders after early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders
pp. 93-94(2)
Authors: Wolterink G.; Daenen L.E.W.P.M.; Dubbeldam S.; Gerrits M.A.F.M.; van Rijn R.; Kruse C.G.; Van Der Heijden J.; Van Ree J.M.

Genetic risk to develop schizophrenia and volume decrease of the thalamus
pp. 94-95(2)
Authors: Hulshoff Pol H.E.; Staal W.; Baare W.F.C.; Schnack H.C.; Kahn R.S.

Schizophrenia: A viral disorder
pp. 95-95(1)
Author: Mednick S.A.

Early life stressors and late life consequences as animal models for schizophrenia
pp. 95-96(2)
Author: Ellenbroek B.A.

Neurobiological basis for the potentiation of antidepressant treatments by pindolol
pp. 96-96(1)
Author: Blier P.

Methodological issues in studies on rapid onset of depression
pp. 97-97(1)
Author: Isaac M.T.

Pindolol augmentation: Single or multiple targets in the brain
pp. 97-98(2)
Author: Artigas F.

Selective serotonin reuptake inhibitors alone and in association with pindolol in the treatment of delusional depression
pp. 98-99(2)
Authors: Zanardi R.; Franchini L.; Gasperini M.; Perez J.; Smeraldi E.

Pindolol augmentation in treatment-resistant panic disorder and obsessive-compulsive disorder
pp. 99-99(1)
Authors: Zohar J.; Dannon P.N.; Sasson Y.; Hirschmann S.; Iancu I.; Grunhaus L.J.

Behavioral disturbances in Alzheimer's disease; description and therapeutic aspects
pp. 99-99(1)
Authors: Robert P.H.; Bertogliati C.; Dygai I.; Migneco O.; Darcourt J.; Pringuey D.

Altering APP trafficing and processing
pp. 100-100(1)
Authors: Beyreuther K.; Masters C.L.

Anti-inflammatory therapeutic strategies in Alzheimer's disease
pp. 100-100(1)
Authors: Bauer J.; Hull M.; Fiebich B.; Lieb K.; Berger M.

Reduced neuronal activity and reactivation in Alzheimer's disease
pp. 100-101(2)
Author: Swaab D.F.

Estrogens: Putative protective agents for Alzheimer's disease
pp. 101-102(2)
Author: Henderson V.W.

Cytokines and depression
pp. 102-103(2)
Author: Leonard B.E.

Cytokines and anhedonia: Evidence from animal studies
pp. 103-103(1)
Author: Aubert A.

Serotonergic systems involved in stress-induced anhedonia
pp. 104-104(1)
Authors: Moreau J.-L.; Bos M.; Gaudet L.; Jenck F.; Martin J.R.; Mortas P.

Opioids and emotional stress
pp. 104-105(2)
Authors: Wiegant V.M.; Schouten W.G.P.; Loyens L.W.S.; van den Berg C.L.; Wolterink G.; van Ree J.M.

Stress, serotonin and the hypothalamic-pituitary-adrenocortical axis
pp. 105-106(2)
Authors: Reul J.M.H.M.; Gesing A.; Penalva R.G.; Bilang-Bleuel A.; Linthorst A.C.E.

Genetics and neurobiology of autism: A modular approach
pp. 106-106(1)
Authors: Leckman J.F.; Schultz R.T.; State M.; Klin A.; Gore J.C.; Volkmar F.R.

Molecular genetics of autism
pp. 106-107(2)
Author: Cook E.H.

Fragile X-syndrome and autism: Is there a relationship at the molecular level?
pp. 107-107(1)
Author: Warren S.T.

Psychopharmacology of autism
pp. 107-107(1)
Author: McDougle C.J.

New approaches to the neurobiology of autism
pp. 107-108(2)
Author: Insel T.R.

Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997
pp. 108-108(1)
Authors: Uhlenhuth E.H.; Balter M.B.; Ban T.A.; Yang K.

Restrictions on benzodiazepine use: Do they make sense?
pp. 108-109(2)
Author: Lader M.

The use of benzodiazepines in anxiety and other disorders
pp. 109-110(2)
Author: Nutt D.J.

The use and development of benzodiazepines in Japan
pp. 110-111(2)
Author: Yamawaki S.

Current epidemiological findings and diagnostic issues in PTSD
pp. 111-112(2)
Authors: Zohar J.; Sasson Y.; Chopra M.; Amital D.; Iancu I.; Zinger Y.

Prospective follow up studies of PTSD: Psychological and biological predictors
pp. 112-113(2)
Author: Shalev A.Y.

Current treatment approaches to PTSD
pp. 113-113(1)
Authors: Davidson J.R.T.; Sutherland S.M.

Advances in Neuroimaging of PTSD: PET and MRI studies
pp. 113-114(2)
Authors: Rauch S.L.; Shin L.M.; Whalen P.J.; Pitman R.K.

Risk factors for suicide attempts: Epidemiological evidence
pp. 114-114(1)
Author: Lecrubier Y.

Anxiety and carotid and intracranial ultrasonographic measurements
pp. 115-115(1)
Authors: Paterniti S.; Bisserbe J.-C.; Courbon D.; Alperovitch A.

Corticotropin releasing factor receptors: Role in depression and therapeutic strategies
pp. 115-116(2)
Authors: De Souza E.B.; Grigoriadis D.E.; McCarthy J.R.

Central and peripheral serotonergic correlates in violent suicidal attempters
pp. 116-117(2)
Authors: Varoquaux-Spreux O.; Cremniter D.

Association and linkage findings in affective disorders
pp. 117-117(1)
Authors: Souery D.; Mendlewicz J.

Dopamine D4 receptor gene polymorphism and human behaviors
pp. 117-118(2)
Author: Benjamin J.

Serotonin transporter: From allelic variation in functional expression to gene knock-out
pp. 118-119(2)
Author: Lesch K.P.

Implication of transgenic models for mental disorders: Study of the dopamine neurotransmission system
pp. 119-119(1)
Authors: Spielewoy C.; Roubert C.; Hamon M.; Giros B.

Magnetic field (MF) affects 5-HT_1B receptor function in brain: Molecular and cellular studies
pp. 120-120(1)
Authors: Massot O.; Grimaldi B.; Bailly J.-M.; Kochanek M.; Deschamps F.; Lambrozo J.; Filliont G.

Transcranial magnetic stimulation in mania
pp. 120-121(2)
Authors: Belmaker R.H.; Grisaru N.

Effect of rTMS and ECT on gene expression: Same or different antidepressant mechanisms
pp. 121-122(2)
Authors: Schlapfer T.E.; Rupp F.; Fisch H.-U.; Hess C.W.

Functional neuroimaging studies of TMS: SPECT, PET and fMRI
pp. 122-123(2)
Authors: George M.S.; Bohning D.E.; Nahas Z.; Shastri A.; Lorberbaum J.P.; Speer A.M.; Vincent D.J.; Roberts D.; Stallings L.E.; Teneback C.; Blumenthal K.

Repetitive transcranial magnetic stimulation trials in depression
pp. 123-124(2)
Authors: Pascual-Leone A.; Keenan J.; Freund S.; Stinchfield Z.; Tormos J.M.; Parker A.; Ives J.; Erb J.; Bimbaum R.

An overview of OCD in child psychiatry
pp. 124-124(1)
Author: Flament M.F.

Auto-immune findings in OCD spectrum disorders and their implications for treatment
pp. 125-125(1)
Authors: Hollander E.; Delgiudice-Asch G.; Cartwright C.; DeCaria C.; Bienstock C.

Neuroreceptors and OCD subtyping
pp. 125-125(1)
Author: Marazziti D.

Brain imaging as a tool to predict treatment response
pp. 126-126(1)
Authors: Hendler T.; Goshen E.; Sasson Y.; Koren E.; Lustig M.; Zohar O.; Zwast S.T.; Zohar J.

Nicotinic receptors subunits and nicotine reinforcement investigated with knock-out mice
pp. 127-127(1)
Authors: Picciottol M.R.; Zolil M.; Rimondini R.; Lena C.; Marubiol L.M.; Pich E.M.; Fuxe K.; Changeux J.-P.

The pharmacology of neuronal nicotine receptor selective ligands
pp. 127-128(2)
Authors: Lloyd G.K.; Menzaghi F.; Rao T.S.; McDonald I.A.

Nicotine and nicotinic receptors in neuronal injury. Focus on basic FGF mechanisms
pp. 128-128(1)
Authors: Belluardo N.; Blum M.; Mudo G.; Fuxe K.

Nicotinic receptors: Therapeutic potential in neurological disease
pp. 129-130(2)
Author: Nordberg A.

Schizophrenia and nicotinic receptors: Gene expression and genetic linkage studies
pp. 130-131(2)
Authors: Leonard S.; Breese C.R.; Gault J.; Adler L.; Olincy A.; Lee M.; Freedman R.

SSRI antidepressant use patterns and their relation to clinical global impressions scores: A naturalistic study
pp. 133-133(1)
Authors: Hylan T.; Meneades L.; Crown W.; Sacristan J.; Gilaberte I.; Montejo A.

Severity gradation of the MADRS in depressed outpatients
pp. 133-133(1)
Author: Benazzi F.

Atypical depression in depressed outpatients: A 203-case study
pp. 133-134(2)
Author: Benazzi F.

Prevalence of severe depression in 203 depressed outpatients
pp. 134-134(1)
Author: Benazzi F.

The effect of adherence to guidelines for depression treatment on relapse and recurrence in a Medicaid population
pp. 134-134(1)
Authors: Melfit C.; Chawla A.; Croghant T.; Hanna M.; Kennedy S.; Sredl K.; Hylan T.

Stability of citalopram hydrochloride in IV solutions and compatibility in the presence of commonly used anxiolytic IV drugs
pp. 134-135(2)
Authors: Gury C.; Sellah Y.; Dolizy I.

Cost effective study of a year follow-up of SSRI and augmentor combination compared to SSRI and placebo
pp. 135-135(1)
Authors: Tome M.B.; Isaac M.

Comparison of the results of differard statistical analysis on the same data set with the aim of showing early onset of action of antidepressants
pp. 135-135(1)
Authors: Niklson I.A.; Reimitz P.-E.

Cost-utility of miinacipran (Ixel(R)) in the prevention of recurrent depression
pp. 136-136(1)
Authors: Dardennes R.; Berdeaux G.; Bisserbe J.C.; Lafuma A.; Pribil C.; Fagnani F.

IDS-C and IDS-SR: Psychometric properties in depressed in-patients
pp. 136-136(1)
Authors: Corruble E.; Legrand J.M.; Duret C.; Zvenigorowski H.; Guelfi J.D.

Differences between clinician-ratings and self-ratings of depressive symptoms: Implication of personality and other psychiatric symptoms
pp. 136-136(1)
Authors: Corruble E.; Legrand J.M.; Zvenigorowski H.; Duret C.; Guelfi J.D.

Double-blind randomised trial assessing the efficacy of citalopram in controlling subjective phobic symptoms in patients with panic disorder
pp. 137-137(1)
Authors: Leinonen E.; Lepola U.; Wade A.; Lehto H.; Pedersen V.

Prescription relevant diagnosis and responder rates in the use of venlafaxine in psychiatry care settings
pp. 137-137(1)
Authors: Sprenger R.; Ripkens-Reinhard A.; Munz T.; Lorkowski G.

Efficacy of venlafaxine (Efexor(R)) in patients with bipolar affective disorder. Results of a pharmacoepiderniological investigation in usual psychiatry care setting
pp. 137-138(2)
Authors: Gastpart M.; Quentin E.; Lorkowski G.

Experience with Venlafaxine (Efexor(R)) in adolescents with depressive disorders
pp. 138-138(1)
Authors: Freisleder F.-J.; Jagusch W.

One versus two weeks exposure to bright light in seasonal affective disorders
pp. 138-138(1)
Authors: Hafinans P.M.J.; Lucius S.A.P.

Lamotrigine in the treatment of affective disorders: A clinical experience
pp. 138-139(2)
Author: Hoopes S.P.

Comparison of research and clinical antidepressant data
pp. 139-139(1)
Authors: Schweizer E.; Perera P.

Are newer antidepressants safe and effective in treating elderly people?
pp. 139-139(1)
Authors: Livingston H.M.; Livingston M.G.

Evaluation of interexaminer reliability in the use of Hamilton depression scale in a multi-site clinical trial about dysthimic disorder
pp. 139-140(2)
Authors: Baca-Garcia E.; Diaz-Sastrel C.; Ricoz F.; Saiz-Ruizl J.

Venlafaxine versus interpersonal psychotherapy for drug naive major depression with sequential HMPAO SPECT scanning
pp. 140-140(1)
Authors: Martin S.D.; Rai S.; Martin E.; Richardson M.; Herring A.; Haywood J.; Barnes A.; Royal R.; Pilowsky L.; Lloyd K.; Davies J.; Vivian G.; Jones I.; Lawrence C.

Efficacy of sertraline in major depression: A study with plasma levels
pp. 140-140(1)
Authors: Mauri M.C.; Bitetto A.; Laini V.; Boscati L.; Fabiano L.; Coppola M.T.

The effect of chronic lithium treatment on PKC-mediated phosphorylation in rat brain
pp. 141-141(1)
Authors: Barki-Harrington L.; Schreiber G.; Avissar S.

Fluoxetine treatment of patients with anxious depression
pp. 141-141(1)
Authors: Sonawalla S.; Pingol M.; Delgado M.L.; Alpert J.E.; Nierenberg A.A.; RosenbaumauM. Fava J.F.; Fava M.

Onset of action in the pharmacologic treatment of dysthymia
pp. 141-141(1)
Authors: Jorit M.C.; Cesana B.M.; Casadeit G.

St. John's wort: Not a substitute for medical evaluation and pharmacotherapy of depression
pp. 142-142(1)
Author: Stokes P.E.

Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study
pp. 142-142(1)
Authors: Rudolph R.; Entsuah R.; Aguiar L.; Derivan A.

Methodology of an observational study concerning the prescription of an antidepressant
pp. 142-143(2)
Authors: Perret I.; Houillon G.; Auquier P.; Begaud B.; Hardy P.; Sambuc R.; San Marco J.L.; Toumi M.

Functional status as predictors of medical offset in anxious and depressed patients
pp. 143-143(1)
Authors: Fifer S.; Henke C.; Potter L.; Mathias S.; Patrick D.; Buesching D.

Depression in primary care settings: Who gets treated and does it change primary care costs?
pp. 143-143(1)
Authors: Henke C.; Potter L.; Fifer S.; Mathias S.; Pasta D.; Buesching D.

The impact of a primary care information exchange program for patients with depression
pp. 144-144(1)
Authors: Beusterien K.M.; Schrammel P.N.; Buesching D.P.; Steinwald A.B.; Goss T.E.

Lamotrigine: Spectrum of antidepressant activity in bipolar disorder
pp. 144-144(1)
Authors: Rudd D.; Ascher J.; Huffman R.; Laurenza A.; Astbury C.; Watson C.; Evoniuk G.

Sertraline treatment of major depressive disorder in a general practice population
pp. 144-145(2)
Authors: Kutcher S.; LeBlanc J.; MacLaren C.C.; Thompson P.; Hadrava V.

Course and cost of treatment with SSRls: A cost-identification analysis
pp. 145-145(1)
Authors: Russell J.M.; Bemdt E.R.; Miceli R.

The selective 5-HT_1A receptor antagonist robalzotan: General pharmacodynamic effects
pp. 145-145(1)
Author: Ojteg G.

Clomipramine concentration: Predictive value with respect to delayed response
pp. 145-146(2)
Authors: Gex-Fabryl M.; Balant-Gorgia A.E.; Balant L.P.

A naturalistic study of mirtazapine in the German psychiatric practice
pp. 146-146(1)
Authors: May F.; Pattenier J.

Pregnancy during use of mirtazapine
pp. 146-146(1)
Authors: Simhandl C.; Zhoglami A.; Pinder R.

Pharmacokinetics of mirtazapine in combination with amitriptyline
pp. 146-147(2)
Authors: Mink L.; Heftink N.; Jonkman J.G.H.; Soedamah S.; Sennef C.

Tolerability of mirtazapine in 15 vs 30 mg initial dose: A randomized, double-blind study
pp. 147-147(1)
Authors: Sitsen A.J.M.; Helsdingen J.T.H.

Efficacy and tolerability of mirtazapine in everyday clinical practice in The Netherlands
pp. 147-147(1)
Authors: Timmerman L.; Helsdingen J.T.H.; Boumans A.A.J.

Efficacy and tolerability of mirtazapine used by elderly depressed patients in The Netherlands
pp. 147-147(1)
Authors: Kat M.G.; Helsdingen J.T.H.; Boumans A.A.J.

From in-vitro genetic alteration to in-vivo NMR imaging, a unique animal model of depression
pp. 147-148(2)
Authors: Wrynn A.S.; Franconi F.; Lemaire L.; Sebens J.B.; Korf J.; deCertaines J.D.; Herhdou S.; MacSweeney C.P.

Venlafaxine and dothispin in depressed elderly patients: A comparison of efficacy and effects on cognition
pp. 148-149(2)
Authors: Stanley N.; Kimber S.; Fairweather D.B.; Hindmarch I.

Thyrotropin and prolactin responses to TRH in delusional (psychotic) and nondelusional depressed patients
pp. 149-149(1)
Authors: Lykouras L.; Markianos M.; Hatzimanolis J.; Papakostas I.

Switching to nefazodone in patients with antidepressant-induced sexual dysfunction
pp. 149-149(1)
Authors: Montejo A.L.; Llorca G.; Uquierdo J.A.; Rico-Villademorost F.

Nuclear effects in situational anxious depressions
pp. 149-150(2)
Authors: Veltischev D.; Gurevich J.; Seravina O.; Chehonin V.

Economic impact of using mirtazaplne in the management of moderate and severe depression in France
pp. 150-150(1)
Authors: Brown M.C.J.; Guest I.F.; van Loon J.

The hypothalamic-pituitary-adrenal axis early feedback response in melancholic depression: A study of venlafaxine therapy
pp. 150-150(1)
Authors: Burnett F.; Cooney J.M.; Dinan T.G.

Fluvoxamine: As effective but safer than clomipramine in severe depression
pp. 150-151(2)
Author: Vekens C.

Fluvoxamine and fluoxetine in the treatment of depression; similarities and differences
pp. 151-151(1)
Author: Dalery J.

The relationship between plasma -endorphin levels and severity of depression
pp. 151-152(2)
Authors: Basturk M.; Muhtawglut S.; Karaaslan M.F.; Oguz A.; Simsek A.; Reyhancan M.

Fluoxetine versus sertraline and paroxetine in major depression: Efficacy and tolerability in patients with high or low baseline insomnia
pp. 152-152(1)
Authors: Favat M.; Rosenbaum J.F.; Hoog S.L.; Tepner R.G.; Kopp J.B.; Sayler M.

Fluoxetine versus sertraline and paroxetine in major depressions Efficacy and tolerability in patients with high or low baseline anxiety
pp. 152-152(1)
Authors: Favat M.; Rosenbaumt J.F.; Hoog S.L.; Tepner R.G.; Kopp J.B.; Sayler M.

Does comorbid anxiety predict antidepressant success or failure?: A meta-analysis of 3800 clinical trial patients
pp. 153-153(1)
Authors: Montornery S.; Porto L.; Plewes J.; Vieira-Brisson T.; Sayler M.; Koke S.; Krupa T.; Pearson D.; Vance L.; Sundell K.

Clinical changes and brain drug concentrations on the third day of substitution of placebo for SSRI treatment
pp. 153-154(2)
Authors: Henr M.E.; Moore C.M.; Stoddard E.; Kaufman M.J.; Barreira P.J.; Vuckovic A.; Renshaw P.F.

Evidence for rating distortion during study lead-in periods: Implications for study design and outcome
pp. 154-154(1)
Authors: Demitrack M.A.; Landin R.; DeBrota D.J.; Faries D.; Potter W.Z.

Predictors of treatment response in major depression
pp. 154-154(1)
Authors: Zivanovic O.; Borisev L.; Borisev V.

Regional cerebral blood flow and depression
pp. 154-155(2)
Authors: Sarchiapone M.; Carli V.; Calvosa F.; Camardese G.; Oricchio I.; De Risio S.

Treatment of depression in patients with chronic HCV related hepatitis and IFN- therapy
pp. 155-155(1)
Authors: Sarchiaponel M.; Oricchiol I.; Camardese G.; Taranto C.; Petti R.; Burrai I.; De Risio S.

Epidemiology and psychopathology of dysthymia
pp. 155-155(1)
Authors: Sarchiapone M.; Mantovani A.; Oricchio I.; Carli V.; Barbarino E.; De Risio S.

Prevalence of affective disorders in an elderly population of Moscow
pp. 155-156(2)
Author: Kalyn Y.B.

Tartu double self-rating scale of mood
pp. 156-156(1)
Authors: Saarma J.; Allikmets E.

Long-term follow-up of venlafaxine in treatment-resistant major depression: A Canadian multicentre open-label trial
pp. 156-156(1)
Authors: Bakish D.; Silverstone P.H.; de Montigny C.

Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
pp. 156-157(2)
Authors: Figueira M.L.; Arriaga F.; Lara E.; Albuquerque A.; Gamito L.

Placebo-controlled trial of the efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
pp. 157-157(1)
Authors: Nemeroff C.B.; Amchin J.

Lithium response correlated with bipolar affective disorders subtypes
pp. 157-157(1)
Authors: Cosman D.; Coman H.

Potentiation of antidepressants with lithium or carbamazepine: Factors associated with therapeutic efficacy
pp. 157-158(2)
Authors: Suwalska A.; Rybakowski J.

Is there a lethargic dimension in non-melancholic depressions?
pp. 158-158(1)
Authors: Cavaglia F.; Matos-Pires A.; Botelho M.; Arriaga F.

Venlafaxine prevents recurrence of depression
pp. 158-158(1)
Authors: Hackett D.; Aguiar L.; Rudolph R.; Entsuah R.

Double-blind trial of venlafaxine and paroxetine for treatment-resistant depression
pp. 159-159(1)
Authors: Schaeffer P.; Poirier M.-F.; Boyer P.

Paroxetine: The preferred choice of patients in the treatment of depression
pp. 159-159(1)
Authors: Geiger M.E.; McCafferty J.; Gergel I.

Depression comorbid with medical illness - Treatment with paroxetine
pp. 159-160(2)
Authors: Tylee A.; McCafferty J.; Gergel I.

Paroxetine in the treatment of severe depression
pp. 160-160(1)
Author: Rouillon F.

Chronobiological model of mood stabilizers effect
pp. 160-160(1)
Author: Mosolov S.

Rapidity in reducing depressive symptomatology: Moclobemide vs amitriptyline
pp. 160-161(2)
Authors: Nedic A.; Lisulov R.; Mogin M.

Correlations between study characteristics and outcome in clinical trials on SSRls and tricyclics in acute depression
pp. 161-161(1)
Authors: Scholin C.; Klein J.; Engel R.R.

Therapeutic efficacy of selective serotonine re-uptake inhibitors. A comparative study
pp. 161-161(1)
Authors: Panteleeva G.P.; Abramova L.I.; Korenev A.N.

Oviedo Sleep Questionnaire (OSQ): A new semistructured Interview for sleep disorders
pp. 162-162(1)
Authors: Bobes J.; Gonzalez M.P.; Vallejo J.; Saiz J.; Gibert J.; Ayuso J.L.; Rico F.

Major depression and insomnia assessed through the Oviedo sleep questionnaire
pp. 162-162(1)
Authors: Bobes J.; Gonzalez M.P.; Ayuso J.L.; Gibert J.; Saiz J.; Vallejo J.; Rico F.

Comparison of the effects of hypericum extracts, imipramine and fluoxetine in rat models of depression and alcoholism
pp. 162-163(2)
Authors: De Vry J.; Maurel S.; Schreiber R.; de Beun R.; Jentzsch K.R.

Tryptophan and catecholamine depletion: Specificity for the neurotransmitter systems in question?
pp. 163-163(1)
Authors: Stastny J.; Rosenthal N.E.; Kasper S.; Neumeister A.

Clinical utility of the hierarchical classification of suicide risk factors
pp. 163-163(1)
Author: Rihmer Z.

Moclobemide monitoring in primary care and psychiatric practice
pp. 163-164(2)
Authors: Timotijevic I.; Aleksic S.; Todorovic M.; Marjanovic A.; Kukuric L.

The treatment of cognitive symptoms of adolescent endogenous depressive disorders
pp. 164-164(1)
Authors: Oleichik I.V.; Artiouch V.V.

Bipolar II versus unipolar atypical outpatient depression
pp. 164-165(2)
Author: Benazzi F.

A historical comparison of four antidepressants
pp. 165-165(1)
Authors: Hoencamp E.; Haffmans P.M.J.; Huijbrechts I.P.M.; Dijken W.A.

Fluoxetine versus tianeptine in elderly depressed
pp. 165-165(1)
Author: Guelfi J.D.

Economic impact of using mirtazapine in the management of moderate and severe depression in Austria
pp. 165-166(2)
Authors: Brown M.C.J.; Nimmerrichter A.A.; Guest J.F.

Efficacy of venlafaxine (Efexor(R)) in patients who prematurely terminated antidepressive therapy due to inefficacy. Results of a pharmacoepidemiological investigation in usual psychiatry care setting
pp. 166-166(1)
Authors: Sauer H.; Quentin E.; Lorkowski G.

Primary care antidepressant treatment and healthcare resource utilization: Evidence from the United Kingdom
pp. 166-166(1)
Authors: Treglia M.; Neslusan C.; Dunn R.

Antidepressant prescribing patterns and risk of relapse and recurrence of depression in a primary care cohort in the United Kingdom
pp. 166-167(2)
Authors: Lil Z.; Claxton A.J.; McKendrick J.

The effect of treatment with a new antidepressant: INN 00835 on platelet serotonin uptake in depressed patients
pp. 167-167(1)
Authors: Leonard B.E.; Nicolau G.; Redmond A.; Kelly R.; Sverdlov L.; Feighner J.; Molinar R.; Noble J.

Effect of venlafaxine and paroxetine on 8-OH-DPAT induced hypothermia in mice
pp. 167-168(2)
Authors: McAllister-Williams R.H.; Alderson E.; McIntire M.; Young A.H.

PET determination of robalzotan occupancy of 5-HT_1A receptors in the monkey brain
pp. 168-168(1)
Authors: Farde L.; Andree B.; Ginovart N.; Halldin C.; Thorberg S.-O.

No change in responsiveness of 5-HT_1A receptors after long-term treatment with the novel 5-HT_1A receptor antagonist robalzotan (NAD-299) in rats
pp. 168-169(2)
Authors: Jackson D.M.; Wallsten C.E.; Larsson L.-G.; Lindgren L.-M.; Bengtsson A.; Ross S.B.

The influence of the atypical antidepressant trimipramine on long term potentiation in guinea pig hippocampal slices
pp. 169-169(1)
Authors: Langosch J.M.; Berger M.; Walden J.

Mirtazapine: New pharmacological method for opioid detoxification
pp. 169-169(1)
Authors: Bendtsen P.; Davood J.

The Hampshire depression project: A randomised controlled trial of the effectiveness of primary care education on the recognition and outcome of depression
pp. 169-169(1)
Authors: Thompson C.; Peveler R.C.; Kinmonth A.-L.; Stevens A.; Ostler K.; Stevens L.

Autoradiographic studies of the labelling of 5-HT_1A receptors in the post-mortem human brain using [¹¹C]NAD-299 and [³H]NAD-299
pp. 170-170(1)
Authors: Hall H.; Halldin C.; Sandell J.; Werner T.; Thorberg O.; Sedvall G.

Amitriptyline vs. moclobemide in depression - A pharmacoeconomic treatment analysis
pp. 170-170(1)
Authors: Marinkovic O.; Timotijevic I.

Does the 5-HT_IA agonist, flesinoxan and the serenic, eltoprazine have antidepressant properties? - An investigation in three rodent paradigms
pp. 170-171(2)
Authors: Cryan J.F.; Redmond A.M.; Kelly J.P.; Leonard B.E.

Chronic pindolol treatment and major affective disorders
pp. 171-171(1)
Authors: Tiihonen J.; Rasanen P.; Hakko H.

Does weight change following recovery from depression? Evidence from a randomized, placebo-controlled trial with fluoxetine
pp. 171-171(1)
Authors: Amsterdam J.; Michelson D.; Kim Y.; Sundell K.

A comparison of symptoms following treatment interruption: Evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine
pp. 171-172(2)
Authors: Fava M.; Rosenbaum J.F.; Hoog S.L.; Krebs W.; Dillon J.A.

Pattern analysis of early relapse during a study of long-tern antidepressant efficacy of fluoxetine hydrochloride
pp. 172-172(1)
Authors: Schmidt M.E.; Michelson D.; Kim Y.; Stewart J.; Quitkin F.

Effects of moderate and intensive training on the sensitivity of 5-HT_1b receptors in rat brain
pp. 172-173(2)
Authors: Chennaoui M.; Fillion M.-P.; Grimaldi B.; Guezennec C.-Y.; Fillion G.

Mapping of [³H]5-HT-moduline binding sites in rodent, guinea-pig and human brains: Film autoradiography and -imaging approaches
pp. 173-173(1)
Authors: Cloez-Tayarani I.; Cardona A.; Pontonnier F.; Sarhan H.; Rousselle J.C.; Massot O.; Cervera P.; Poirie M.F.; Lecomte D.; Edelman L.; Fillion G.

5-HT-moduline specifically interacts with human 5-HT_1B and 5-HT_1D receptors
pp. 173-173(1)
Authors: Massot O.; Rousselle J.C.; Fillion M.P.; Plantefol M.; Fillion G.

Two cases of the serotonin syndrome occurring after abruptly switching antidepressants
pp. 174-174(1)
Authors: Zivanovic O.; Borisev L.; Borisev V.

Recurrent brief depression: Clinical and therapeutic aspects
pp. 174-174(1)
Authors: Amore M.; Ricci M.; Ferrari G.

Dissociation of glucocorticold receptor-heat shock protein (HSP) complex in rat hippocampus after chronic unpredictable stress
pp. 174-175(2)
Authors: Asakura M.; Sasuga Y.; Matsushita T.; Hagiya T.; Bodaiji N.; Hasegawa H.; Osada K.; Imafuku J.

In vivo rat brain microdialysis studies of the new 5-HT_1A receptor antagonist robalzotan
pp. 175-175(1)
Author: Hjorth S.

Randomized, double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression
pp. 175-175(1)
Authors: Benedictis E.; Moreno R.; Gentil V.; Busnello E.D.; Correa F.K.; Campos J.A.

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with mild to moderate depression or dysthmia
pp. 175-176(2)
Authors: Ballus C.; Quiros G.; de Flores T.; de la Torre J.; Palao D.; Rojo L.; Gutierrez M.; Casais L.; Riesgo Y.

Comorbidity of personality disorders and dysthymia - Implications for treatment
pp. 176-176(1)
Author: Lecic-Tosevshi D.

Neurophysins and temperature responses to flesinoxan, a 5-HT_1A agonist, in major depression: Relationship with suicidal behavior
pp. 176-177(2)
Authors: Pitchot W.; Hansenne M.; Ansseau M.; Legros J.-J.

Randomized, double-blind comparison of venlafaxine and fluoxetine for moderately depressed outpatients
pp. 177-177(1)
Author: Nannenga P.

Dopamine agonists treatment of chronic depressive patients resistant to tricyclic antidepressants
pp. 177-177(1)
Authors: Mosolov S.; Tsukarzi E.; Missionznik E.; Sharov A.; Uzbekov M.

General practitioners' knowledge of antidepressant discontinuation reactions
pp. 177-178(2)
Authors: Haddad P.; Tylee A.; Young A.

Olanzapine versus placebo in the treatment of acute mania
pp. 178-178(1)
Authors: Tohen M.; Sanger T.M.; McElroy S.L.; Tollefson G.D.; Grundy S.L.; Greaney M.; Jacobs T.; David S.; Andersen S.; Toma V.

Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features
pp. 178-178(1)
Authors: Tollefson G.D.; Shelton R.; Tohen M.; Stahl S.; Jacobs T.; Buras W.; Gannon K.S.; Spencer K.A.

Synthetic pathways of 3-reduced neuroactive steroids in major depression and after clinical recovery
pp. 179-179(1)
Authors: Strohle A.; Romeo E.; Hermann B.; Holsboer F.; Runpprecht R.

Do WML contribute to the subsequent development of dementia in patients with mild cognitive impairment?
pp. 179-179(1)
Authors: Wolf H.; Ecke G.; Grunwald M.; Angerhofer S.; Zedlick D.; Gertz H.-J.

Central serotonin transporter density in symptomatic depressed SAD patients and healthy controls
pp. 179-179(1)
Authors: Willeit M.; Praschak-Rieder N.N.; Pirker W.; Neumeister A.; Stastny J.; Hilger E.; Asenbaum S.; Brucke T.; Kasper S.

The contribution of ovarian steroids to early postnatal depression
pp. 179-180(2)
Authors: Lovett K.; Wieck A.; Appleby L.

The novel 5-HT_1A receptor antagonist, robalzotan, reverses the SSRI-induced inhibition of serotonergic cell firing in the dorsal raphe nucleus in the rat
pp. 180-180(1)
Authors: Arborehus L.; Wallsten C.; Ablenius S.; Svensson T.H.

Characterization of the in vitro receptor binding properties of the novel selective 5-HT_1A antagonist [³H]robalzotan
pp. 180-181(2)
Authors: Jerning E.; Svantesson G.T.; Mohell N.

Gabapentin, an alternative drug in the prophylaxis of bipolar disorders: Preliminary data
pp. 181-181(1)
Authors: Mauri M.C.; Laini V.; Scalvini M.; Steinhilber C.P.C.; Invernizzi G.

Effects of pre-treatment with paroxetine and venlafaxine on neuroendocrine responses to L-tryptophan
pp. 181-181(1)
Authors: Porter R.J.; Jones S.J.; Leitch M.M.; Nelson D.M.; Young A.H.

Polygraphic study of the effects of milnacipran 100 mg on the sleep of depressed in-patients
pp. 181-182(2)
Authors: Faivre T.; Lemoine P.; Bisserbe J.C.; Schwenk B.

Paroxetine induced changes in the neurological function of serotonin in rat medial prefrontal cortex - Microdialysis study
pp. 182-182(1)
Authors: Wakutsu N.; Nakayama K.; Katsu H.; Koga M.; Miyata H.; Ushijima S.

Population pharmacokinedcs of clomipramine: Model development and application in a clinical prospective study
pp. 182-183(2)
Authors: Haffen E.; Paintaud G.; Gex-Fahry M.; Broly F.; Bizouard P.; Sechter D.; Balant L.P.; Bechtel P.R.

A comparison of the effects of bupropion SR and sertraline on sexual functioning in depressed outpatients
pp. 183-183(1)
Authors: Batey S.R.; Hughes A.R.; Ascher J.A.; Donahue R.M.J.

Evidence of the activity of lithium on 5-HT_1B receptors in the mouse forced swimming test: Comparison with carbamazepine and sodium valproate
pp. 183-183(1)
Authors: Bourin M.; Redrobe J.P.

Effects of robalzotan on neostriatal rate of serotonin and dopamine synthesis in rats, normally and under psychomotor activation
pp. 183-184(2)
Authors: Ahlenius S.; Salmi P.; Henriksson I.

Effects of amphetamine and phencyclidine on brain monoamines and neuropeptides in haloperidol pretreated rats
pp. 184-184(1)
Authors: Mathe A.A.; Gruber S.H.M.; Theodorsson E.

Chronic lithium alters stress-induced c-fos and AP-1 binding activity in rat brain
pp. 184-184(1)
Authors: Mathe A.A.; Miller J.C.; Jimenez P.

In vitro-in vivo extrapolation of robalzotan metabolic parameters: an interspecles comparison
pp. 184-185(2)
Authors: Milchert I.G.; Gabrielsson J.; Linde J.; Terelius Y.

Pharmacokinetics of robalzotan in rats and dogs including in vitro and in vivo data on metabolism
pp. 185-185(1)
Authors: Milchert I.G.; Berg A.; Berin B.; Breuer O.; Knowles S.; Lindgren J.-E.; Martinsson S.; Roberts D.; Sokolnicka A.; Wikstrom S.-A.

In vitro metabolism of S-(+)- and R-(-)-enantiomers of mirtazapine
pp. 185-185(1)
Authors: Delbressine L.P.C.; Gloudemans R.H.M.; Verhoeven C.H.J.; Vos R.M.E.; Pinder R.M.; Organon N.V.

The use of mirtazapine in primary care in Germany
pp. 185-185(1)
Authors: Kreuzenbeck H.-J.; Zivkov M.; Organon N.V.

Effects of nefazodone on the immune system of mice
pp. 185-186(2)
Authors: Freire-Garabal M.; Nunez M.J.; Riveiro P.; Varela M.; Fernandez-Rial J.C.; Suarez J.; Mayan J.M.; Rey-Mendez M.

Frequency of sleep disturbance in major depression
pp. 186-186(1)
Authors: Ayuso J.L.; Bobes J.; Gibert J.; Saiz-Ruiz J.; Vallejo J.; Rico F.

Effect of bipolar disorder and Lithium treatment on inositol monophosphatase transcription and translation in lymphoid cells
pp. 186-186(1)
Authors: Agam G.; Shamir A.; Belmaker R.H.; Nemanov L.; Ebstein R.P.

Experience of antidepressant drug/fluoxetineltherapy of colitis ulcerosa patients suffering from depression
pp. 186-187(2)
Authors: Ostorharics G.; Radics J.

Fluoxetine and ammitriptyline in the treatment of major depression with associated anxiety
pp. 187-187(1)
Authors: Versiani M.; Plewes J.; Ontiveiros A.; Mazzotti G.; Ospina J.; Davila J.; Mata S.; Pacheco A.; Tamura R.; Palacios M.; Vance L.; Marietegui J.; Nardi A.

Modulation of serotonin transporter function by brain-derived neurotrophic factor but not by nerve growth factor
pp. 187-187(1)
Authors: Mossner R.; Hiels A.; Stober G.; Lesch K.P.

¹²³I-IBZM-SPECT imaging in psychotic depression
pp. 187-187(1)
Authors: Sarchiapone M.; Camardese G.; Carli V.; Calvosa F.; Taranto C.; De Risio S.

Viral reactivation in relation to immune activation in major depression
pp. 187-188(2)
Authors: Sluzewska A.; Rybakowski J.; Suwalska A.

Immunological study of manic patients
pp. 188-188(1)
Authors: Mubarak A.; Gad E.; Ibrahim W.

Role of 5-HT_1A somatodendritic receptors in the interaction antidepressants-opiates
pp. 188-188(1)
Authors: Mico J.A.; Ortega-Alvaro A.; Roca A.; Gibert-Rahola J.

Adaptations of the central serotoninergic neurotransmission in mice lacking the 5-HT transporter (5-HTT)
pp. 188-189(2)
Authors: Fabre V.; Lacour C.M.; Rioux A.; Hanoun N.; Martres M.P.; Lesch K.P.; Hamon M.; Lanfumey L.

Effect of sertraline and paroxetine treatment on depression scores and peripheral indices of serotonergic function in major depression
pp. 189-189(1)
Authors: Khoury A.; Aberg-Wistedt A.; Stain-Malragren R.

Effects of long-term lithium treatment on monoaminergic and neuroendocrine functions in major depression
pp. 189-189(1)
Authors: El Khoury A.; Johnson L.; Mathe A.; Aberg-Wistedt A.; Stain-Malmgren R.

Onset of action, mociobemide vs fluoxetine, in depressive episode with somatic symptoms
pp. 189-190(2)
Authors: Nedic A.; Stokin B.; Lisulov R.; Cvjetkovic-Bosnjak M.; Mogin M.

Genetic study of dopamine-related genes in unipolar affective disorder
pp. 190-190(1)
Authors: Papadimitriou G.N.; Dikeos D.G.; Karadima G.; Daskalopoulou E.G.; Avramopoulos D.; Stefanis C.N.

Treatment of agitated psychosis: Magnesium sulphate i.v. as an adjunctive therapy
pp. 190-190(1)
Authors: Heiden A.; Blasbichler T.; Frey R.; Presslich O.; Smetanat R.; Kasper S.

Association study between bipolar disorder and candidates genes involved in dopamine metabolism
pp. 191-191(1)
Authors: Nilsson L.; Heiden A.; Scharfetter J.; Fuchs K.; Urmann A.; Willeit M.; Lang T.; Gerhard E.; Fathi N.; Stompe T.; Sieghart W.; Kasper S.; Aschauer H.N.

Role of 5-HTTLPR in seasonal affective disorder (SAD) with and without premenstrual dysphoric disorder (PMDD)
pp. 191-191(1)
Authors: Praschak-Rieder N.; Willeit M.; Neumeister A.; Stastny J.; Hilger E.; Lenzinger E.; Fuchs K.; Vitouch O.; Aschauer H.N.; Sieghart W.; Kasper S.

Magnesium-adjacent for the therapy of depressive disorders
pp. 191-191(1)
Authors: Zaharia C.E.; Alexandru D.I.

SSRI discontinuation syndrome treated with fluoxetine
pp. 192-192(1)
Author: Benazzi F.

Venlafaxine interaction with psychoactive drugs
pp. 192-192(1)
Author: Benazzi F.

Gabapentin and valproate as an adjunct in the neuroleptic treatment of manic syndromes
pp. 192-193(2)
Authors: Alberti G.G.; Garini R.; Marzolini M.; Beltz J.; Felcher A.; Greco M.I.; Maresca G.

Effect on HPA of olanzapine, pindolol, dexamethasone and antidepressants in resistant depression
pp. 193-193(1)
Authors: Tome M.B.; Isaac M.

Cerebrospinal fluid inositol monophosphatase: elevated activity in depression and neuroleptic-treated schizophrenia
pp. 193-193(1)
Authors: Atack J.R.; Dobrusin M.; Levine J.; Belmaker R.H.

The benefits of intravenous versus oral citalopram in severely depressed patients: results of two double-blind studies
pp. 193-194(2)
Authors: Baumann P.; Guelfi J.D.; Nil R.; Strub N.; Loft H.

A double-blind study to evaluate the advantage of citalopram infusion over oral citalopram in the treatment of severe depression
pp. 194-194(1)
Authors: Guelfi J.D.; Strub N.; Loft H.

Effect of chronic antidepressant treatment on behavioural, neurochemical and endocrine changes following forced swim test exposure
pp. 194-194(1)
Authors: Connor T.J.; Kelliher P.; Shen Y.; Harkin A.; Kelly J.P.; Leonard B.E.

Lamotrigine does not cause clinically relevant changes in the pharmacokinetics of lithium
pp. 194-195(2)
Authors: Veronese L.; Chen C.; Peck R.

Lack of antimanic efficacy of the GABA transporter 1 inhibitor tiagabine
pp. 195-195(1)
Authors: Grunze H.; Erfurth A.; Marcuse A.; Amann B.; Normann C.; Walden J.

Trimipramine shows no antimanic action - A discrepancy between in vitro rationale and clinical efficacy
pp. 195-195(1)
Authors: Erfurth A.; Normann C.; Grunze H.; Amann B.; Walden J.

Mirtazapine vs fluoxetine: Efficacy on symptoms associated with depression
pp. 195-196(2)
Authors: Kremer C.M.E.; Schutte A.J.; Organon N.V.

Effects of venlafaxine on REM sleep after short term and long term application in patients with major depression
pp. 196-196(1)
Authors: Hemmeter U.; Bruderlin U.; Hatzinger M.; Armen B.; HolsboerTrachsler E.

Effects of short and long-term lithium treatment on serum cortisol levels in patients with bipolar affective disorder
pp. 196-196(1)
Authors: Basturk M.; Sofuoglu S.; Karaaslan F.; Tutus A.; Yabanoglu I.; Gonul A.S.

Venlafaxine withdrawal syndrome
pp. 196-197(2)
Authors: Ricci M.; Amore M.; Papalini A.

Once-daily venlafaxine XR vs. paroxetine in outpatients with major depression
pp. 197-197(1)
Author: Salinas E.

Open-label evaluation of once-daily venlafaxine XR in depressed outpatients
pp. 197-197(1)
Authors: Hackett D.; Parks V.; Salinas E.

Antidepressive and anxiety-lowering effects of immunotherapy and aromatherapy
pp. 197-198(2)
Authors: Nevidimova T.; Kupriyanova I.; Zapuskalova E.; Semke V.

The lithium adverse effects in bipolar affective patients - Long term study
pp. 198-198(1)
Authors: Nikolic M.; Vezmar M.; Zdravkovic M.; Timotijevic I.

Monoaminergic challenge paradigms in seasonal affective disorder
pp. 198-198(1)
Authors: Neumeister A.; Praschak-Rieder N.; Willeit M.; Rosenthal N.E.; Kasper S.

Mirtazapine in menopausal depression
pp. 198-199(2)
Authors: Tome M.B.; Isaac M.

The efficacy of milnacipran (IxeI^R) in the prevention of recurrent depression: Effects on quality of life
pp. 199-199(1)
Authors: Rouillon F.; Berdeaux G.; Chwalow J.; Mesbah M.

Time-dependent effects of antidepressant drugs on the reactivity of the rat dopamine D3 receptors
pp. 199-199(1)
Authors: Dziedzicka-Wasylewska M.; Rogoz Z.

Neurochemical pathology of the noradrenergic locus coeruleus in major depression: Postmortem studies
pp. 199-200(2)
Authors: Klimek V.; Zhu M.-Y.; Ordway G.A.

A European multicenter association study of bipolar and unipolar disorders with dopamine receptor polymorphisms: DRD2, DRD3 and DRD4
pp. 200-200(1)
Authors: Rivelli S.K.; Souery D.; Lipp O.; Verheyen G.; aeymaekers P.; Serretti A.; Macciardi F.; Van Broeckhoven C.; Mendlewicz J.

An open assessment of the efficacy and tolerability of Venlafaxine in a large population treated in usual psychiatry care setting: Comparison of inpatients and outpatients
pp. 200-200(1)
Authors: Quentin E.; Lorkowski G.

No major pathology in the human hippocampus in major depression or following administration of glucocorticoids. A study on human post-mortem tissue
pp. 201-201(1)
Authors: Muller M.B.; Lucassen P.J.; Yassouridis A.; Hoogendijk W.J.G.; Holsboert F.; Swaab D.F.

Alterations in sensorial perception during mood disorders
pp. 201-201(1)
Authors: Smaili R.; Hoencamp E.; Jonker K.; Haffmans P.M.J.; Birkenhager T.K.

General practitioner's and psychiatrist's treatment recommendations in depression and anxiety
pp. 201-202(2)
Authors: McAllister-Williams R.H.; Macaulay A.

Sertraline and IPT in dysthymia: One year follow-up
pp. 202-202(1)
Authors: Steiner M.; Browne G.; Roberts J.; Gafni A.; Byrne C.; Bell B.; Dunn E.

Comparison of the safety and efficacy of bupropion sustained release and paroxetine in elderly depressed outpatients
pp. 202-202(1)
Authors: Batey S.; Ascher J.A.; Donahue R.M.J.; Houser T.L.

Compliance with antidepressant treatment of depression in primary care in the UK
pp. 202-203(2)
Authors: McKendrick J.; Stephenson D.A.; Thompson C.; Peveler R.C.

Continuation and maintenance electroconvulsive therapy in elderly depressed patients
pp. 203-203(1)
Authors: Sigler M.; Aizenberg D.; Weizman A.

Modulation of presynaptic release machinery by typical and typical antidepressants
pp. 203-204(2)
Authors: Zanotti S.; Verona M.; Gaggianesi C.; Radaelli R.; Schaeferz T.; Racagni G.; Popoli M.

Fluoxetine versus sertraline and paroxetine in major depression: Long-term changes in weight
pp. 204-204(1)
Authors: Fava M.; Rosenbau J.; Hoog S.; Millard D.; Tepner R.

Immunohistochemistry of 5-HT_1B receptors in mouse peripheral tissues
pp. 204-204(1)
Authors: Sibella-Arguelles C.; Grimaldi B.; Fillion M.-P.; Fillion G.

Acute stress induces a differential increase of 5-HT moduline levels In various rat brain areas
pp. 204-205(2)
Authors: Bonnin A.; Grimaldi B.; Fillion M.-P.; Fillion G.

5-HT moduline metabolism in mammalian brain: Identification of two enzymatic activities
pp. 205-205(1)
Authors: Plantefol M.; Rousselle J.C.; Fillion G.

5-HT_1B receptor stimulation inhibits the K⁺-evoked [³H]dopamine release from rat striatal synaptosomes
pp. 205-206(2)
Authors: Sarhan H.; Cloez-Tayarani I.; Massot O.; Fillion M.P.; Fillion G.

Pharmacological heterogeneity of 5-HT_1B auto-and heteroreceptors
pp. 206-206(1)
Authors: Sarhan H.; Cloez-Tayarani I.; Massot O.; Fillion M.P.; Fillion G.

Identification of the enzymes involved in the primary pathways of tianeptine using human in vitro models
pp. 206-206(1)
Authors: Mocquardt M.T.; Proust L.; Deslandes A.; Chezaubemard C.; Bertrand M.

Normalization of Padrenoceptor down-regulation by SSRI under chronic stress: A mechanism of action of prophylactic effects of antidepressant drugs
pp. 206-207(2)
Authors: Matsushita T.; Asakura M.; Sasuga Y.; Hagiya Bodaiji T.; Osada K.; Hasegawa H.; Aoba A.

Randomized, double-blind comparison of venlafaxine and fluoxetine in hospitalized patients with major depression and melancholia
pp. 207-207(1)
Authors: Tzanakaki M.; Ierodiakonou C.; Dimitriou E.; Alevizos V.

Randomized, double-blind comparison of venlafaxine and sertraline for major depression
pp. 207-207(1)
Authors: Eriksson S.; Behnke K.; Segaard J.; Ostergaard P.; Koskinen T.; Mehtonen O.-P.; Roponen P.

Lithium treatment response in bipolar affective disorder coexisting with multiple sclerosis: A case report
pp. 207-208(2)
Authors: Malitas P.N.; Papadimitriou G.N.; Alevizos B.; Christodoulou G.N.

Clinical subtypes and severity do not influence response of sertrallne in 1656 outpatients with major depression
pp. 208-208(1)
Authors: Guelfi J.D.; Lancrenon S.; Friedman S.

The effects of sub-chronic treatment with the selective 5-HT_1A receptor antagonist robalzotan, 8-OH-DPAT and antidepressive drugs on 5-HT_1A, 5-HT_2A, DA D2 and -adrenergic receptors
pp. 208-208(1)
Authors: Jerning E.; Mohell N.

Reciprocal molecular interaction between 5-HT and 5-HT moduline
pp. 208-209(2)
Authors: Rousselle J.C.; Plantefol M.; Massot O.; Fillion G.

Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression
pp. 209-209(1)
Authors: Hackett D.; Salinas E.; Desmet A.

EEG and SEP monitoring in patients with paroxetin-induced myocionus
pp. 209-210(2)
Authors: Lechner C.; Meisenzahl E.M.; Friess E.; Modell S.

The Munich vulnerability study on affective disorders: Re-assessment and comparative evaluation of DEX-CRH test results after four years
pp. 210-210(1)
Authors: Modell S.; Lauer C.J.; Schreiber W.; Huber J.; Kriegt J.-C.; Holsboer F.

Predictability of unavoidable physical and emotional stress does not affect the stress-induced long-term behavioural changes
pp. 210-210(1)
Authors: Pijlman F.T.A.; Wolterink G.; van Ree J.M.

Influence of long term neuroleptic treatment on male sexual functions
pp. 210-211(2)
Author: Kores B.P.

Predictive factors of therapeutic compliance in schizophrenia
pp. 211-211(1)
Authors: Diaz E.I.S.; Cabeza I.G.; Gutierrez M.; de Chavez M.G.

Risperidone increases serotonin output in the rat frontal cortex: Rote of ₂ and 5-HT_1D receptor antagonism
pp. 211-211(1)
Authors: Svensson T.H.; Hertel P.; Nomikos G.G.

Effects of low doses of amisulpride on psychomotor and memory performances in healthy elderly subjects
pp. 211-211(1)
Authors: Legangneux E.; McEwen J.; Wesnes K.; Bergougnan L.; Miget N.; L'heritierl C.; Pinquier J.L.; Rosenzweig P.

Effects of combined clozapine-tluvoxamine versus clozapins treatment on blood cell counts and plasma levels of cytokines and their receptors
pp. 212-212(1)
Authors: Hinze-Selch D.; Weber B.; Deuschle M.; Heuser I.; Pollmacher T.

Verbal delayed reactions. A study of prefrontal functional impairments in schizophrenic patients
pp. 212-212(1)
Authors: Pinelli P.; Baroni L.; Zara D.; Pellegrino F.

Frontal dysfunction and neuroleptic treatment: A combined fMRI and MRSI study
pp. 212-213(2)
Authors: Braus D.F.; Ende G.; Weber-Fakir W.; Ruf M.; Stuck S.; Henn F.A.

Haloperidol decanoate and fluphenazine decanoate for schizophrenia: A comparative naturalistic medium-term study of efficacy and tolerability
pp. 213-213(1)
Authors: Hranov L.G.; Yanakiev N.; Stefanov S.; Nikolova N.; Yakimova R.

The efficacy of clozapine in 111 schizophrenic patients during a 2-year follow-up period in Turkey
pp. 213-213(1)
Authors: Cosar B.; Tatter E.; Ankan Z.; Isk E.

Involvement of adenosine A_2A receptors in the c-Fos expression induced by clozapine and haloperidol
pp. 213-214(2)
Authors: Wardas J.; Pinna A.; Cozzohno A.; Morelli M.

Quantitative electroencephalography in schizophrenia: therapeutic effects of haloperidol and risperidone
pp. 214-214(1)
Authors: Nagao M.; Mori K.; Kobayakawa M.; Hirayatna S.; Harada Y.; Kashiwagi K.; Irisawa T.; Nagao K.

A comparison of newer vs traditional antipsychotics and placebo using meta-analysis techniques
pp. 214-215(2)
Authors: Wighton A.J.; Ruck A.; Appleby P.; Welch C.P.; Butler A.; Reynolds C.W.; Tweed J.A.

Efficacy of zotepine in schizophrenia - A global meta-analysis
pp. 215-215(1)
Authors: Appleby P.; Wighton A.J.; Ruck A.; Welch C.P.; Butler A.; Reynolds C.W.; Tweed J.A.

The effect of risperldone on behavioral disturbances in mentally retarded children and adolescents
pp. 215-215(1)
Authors: Lemnens P.; De Smedt G.

Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: Population pharmacokinetic modelling
pp. 215-215(1)
Authors: Miceli J.; Wilner K.; Folger C.; Tensfeldt T.; Preskorn S.

A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol
pp. 216-216(1)
Authors: Swift R.H.; Harrigan E.P.; van Kannnen D.; Casey D.E.

The tolerability and efficacy of ziprasidone in the treatment of children and adolescents with Tourette's syndrome
pp. 216-216(1)
Authors: Chappell P.; Sallee F.

Weight gain associated with conventional and newer antipsychotics: A meta-analysis
pp. 216-217(2)
Authors: Allison D.B.; Mentoret J.L.; Hen M.; Weiden P.; Cappelleri J.; Chandler L.P.

Schizophrenia care and assessment program (SCAP): A naturalistic approach to measuring schizophrenia outcomes
pp. 217-217(1)
Authors: Haley J.C.; Russo P.A.; Buesching D.P.

Psychosis and behavioral disturbances in dementia: Effects of risperidone in 969 patients
pp. 217-217(1)
Authors: De Deyn P.P.; De Smedt G.; Brecher M.

Thalamic and ventricular volumes in siblings discordant for schizophrenia and normal controls
pp. 217-218(2)
Authors: Staal W.G.; Pol H.E.H.; Schnack H.G.; van der Schot A.; Kahn R.S.

Impaired flexibility of the hypothalamic-pituitaryadrenal system in schizophrenia
pp. 218-218(1)
Authors: Jansen L.M.C.; Wied C.C.G.-d.; Kahn R.S.

Latent dimensions of depressive and negative symptoms in acute schizophrenia: Treatment effects of high dose amisulpride vs. flupentixol
pp. 218-218(1)
Authors: Miller M.J.; Wetzel H.; Benkert O.

Neuroleptic drug induced movement disorders and catatonic symptoms: Factor analysis of findings in chronic schizophrenia
pp. 218-218(1)
Authors: Hibfer J.; Braunig P.; Borner I.; Kriiger S.

Dosage of risperidone in old and high aged patients
pp. 218-219(2)
Authors: Wittgens W.; Trenclcmann U.

BTS 79 018 - Advantaged pharmacological profile compared to new atypical antipsychotics
pp. 219-219(1)
Authors: Needham P.L.; Skill M.J.; Birch A.M.; Kilpatrick I.C.; Heal D.J.

Drug-induced tardive dyskinesia and mortality: An eight-year follow-up of 36 cases and 36 matched controls
pp. 219-220(2)
Authors: Ballesteros J.; Zabalo M.J.; Jauregui J.V.; Bulbena A.

Onset of action in acute schizophrenia, amisuipride versus haloperidoi
pp. 220-220(1)
Authors: Turjanski S.; Rein W.; Theron M.

Predictors of weight gain during olanzapine treatment
pp. 220-220(1)
Authors: Kinon B.J.; Basson B.; Szymanski K.; Tollefson G.D.

Therapeutic drug monitoring of risperidons: New insight into variability factors
pp. 220-221(2)
Authors: Balant-Gorgial A.E.; Gex-Fabry M.; Balant L.P.

Reliability and validity of the Greek version of the Calgary depression scale for schizophrenics
pp. 221-221(1)
Authors: Kontaxakis V.; Havaki-Kontaxaki B.; Stamouli S.; Margariti M.; Kollias K.; Angelopoulos E.; Jemos J.; Christodoulou G.N.

Treatment of clozapine-induced agranulocytosis with granulocyte-colony-stimulating factor (G-CSF): Three cases
pp. 221-221(1)
Authors: Leotsakou C.; Theodoropouloul S.; Baltathakis I.; Giannakaki A.; Kolovou A.; Gigantes S.; Karmiris T.; Nikiforakis E.

The effect of novel antipsychotics clozapine, olanzapine and risperidone in rat oral dyskinesia and working memory
pp. 221-222(2)
Authors: Rosengarten H.; Quartermain D.; Friedhoff A.J.

Serotonin and dopamine receptor responsivity in schizophrenic patients in drug-free state or on haloperidol, and after treatment with clozapine
pp. 222-222(1)
Authors: Lykouras L.; Hatzimanolis J.; Markianos M.

Fluoxetine addition to risperidone in adult psychotic patients: Pharmacokinstic and clinical consequences
pp. 222-223(2)
Authors: Bondolfi G.; Huang M.L.; De Smedt G.; Eap C.B.; Zullino D.; Baumann P.

Suicidal risk in patients treated with the novel antipsychotic olanzapine
pp. 223-223(1)
Authors: Fung M.; Tran P.; Beasley C.; Tollefson G.; Crawford A.; Brookfield W.

Clozapine versus risperidone: An open, comparative and prospective study on efficacy, tolerability and quality of life
pp. 223-223(1)
Authors: Pajonk F.-G.; Tiessen S.; Holzbach R.; Naber D.

Abortive forms of the neuroleptic malignant syndrome: Four case reports
pp. 223-224(2)
Authors: Zivanovic O.; Borisev L.; Borisev V.

Substance abuse and axis I comorbidity in psychotic disorders
pp. 224-224(1)
Authors: Pini S.; Dell'Osso L.; Mastrocinque C.; Manzi C.; Saettoni M.; Vignoli S.; Papasogli A.; Marcacci G.; Cassano G.B.

Application of the factor pyramidical model in diagnosing and treating schizophrenia
pp. 224-224(1)
Authors: Tacchini G.; Sironi J.; Charitos S.; Fusi O.; Penati G.

Safety of amisulpride (Solian(R)) A pooled review of 11 clinical studies
pp. 225-225(1)
Authors: Coulouvrat C.; Dondey-Nouvel L.; Blanchet S.

Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders
pp. 225-225(1)
Authors: Lane L.M.; Burns P.R.; Reams S.C.; Sanger T.M.; Beasley C.M.

Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
pp. 225-225(1)
Authors: Tollefson G.D.; Sanger T.M.; Andersen S.W.

Resource use and quality of life of olanzapine compared with risperidone; Results from an international randomized clinical trial
pp. 225-226(2)
Authors: Grainger D.; Edgell E.T.; Andersen S.W.; Wang J.

Case report: Tentamen WOO cum 660 mg haloperidol
pp. 226-226(1)
Authors: Stefanovski B.; Paketcieva K.; Cadlovski G.; Manuseva N.; Dimova A.

Efficacy and safety of suipiride in treatment resistant psychoses
pp. 226-226(1)
Authors: Qetin M.; Basoglu C.; Ebrinc S.; Ozcubukcuoglu A.; Evren C.; Burkovikt Y.

An investigation of subgroup effects in a study of olanzapine vs. clozapine In the treatment of resistant schizophrenic patients
pp. 226-227(2)
Authors: Beuzen J.-N.; Birkett M.A.; Kiesler G.M.

No association between tardive dyskinesia and serotonin 2a receptor gene mutations
pp. 227-227(1)
Authors: Aschauer H.N.; Scharfetter J.; Homik K.; Fuchs K.; Gerhard E.; Gebhardt C.; Lenzinger E.; Meszarost K.; Sieghart W.; Kasper S.

Olanzapine versus placebo in rapid-cycling bipolar disorder
pp. 227-227(1)
Authors: Sanger T.; Tohen M.; Tollefson G.; David S.; Greaney M.

The Hashish' role as determining factor of a schizophrenic syndrome
pp. 227-228(2)
Authors: Lorenzo P.; De Notaris-Giuseppe E.; Pillo A.; Merone A.F.

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
pp. 228-228(1)
Authors: Hamilton S.H.; Breier A.; David S.

Long term efficacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine
pp. 228-228(1)
Authors: Mallinckrodt C.; David S.; Burns P.; Breier A.

Olanzapine versus haloperidoi treatment in first-episode psychosis
pp. 228-229(2)
Authors: Sanger T.; Lieberman J.; Tohenl M.; Grundy S.; Beasley C.; Tollefson G.

A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo
pp. 229-229(1)
Authors: Tollefson G.D.; Dellva M.A.; Mattler C.A.; Kinon B.J.; Grundy S.L.

Prolactin levels in olanzapine versus typical and atypical antipsychotics
pp. 229-229(1)
Authors: David S.; Crawford A.M.; Breier A.

Preschizophrenic Wechsler adult intelligence scales performance in 14 to 18 year old adolescents: A follow-back study
pp. 229-230(2)
Authors: Amminger G.P.; Schlogelhofer M.; Aschauer H.

Some aspects of treatment of adolescent schizoaffective disorders
pp. 230-230(1)
Author: Kaleda V.G.

Correlation of striatal dopamine-2 receptor occupancy and extrapyramidal side-effects during antipsychotic treatment: A ¹²³¹IBZM 3PECT study
pp. 230-231(2)
Authors: Tauscher J.; Kufferle B.; Barnas C.; Pezawas L.; Asenbaum S.; Tauscher-Wisniewski S.; Brucke T.; Kasper S.

Risperidone: Cost-effectiveness treatment study with schizophrenic patients
pp. 231-231(1)
Authors: Chinchilla A.; Vega M.; Cebollada A.; Madoz A.; Huertas M.; Zabala S.; Ceverino A.; Garcia V.

Amisulpride improves affective symptoms in acute schizophrenia
pp. 231-231(1)
Authors: Rein W.; Fleurot O.; Turjanski1 S.

Amisulpride in schizophrenia: A review of its efficacy in acute and chronic patients
pp. 231-232(2)
Authors: Moller H.J.; Rein W.; Turjanski S.

Zotepine is effective in preventing recurrence in patients with chronic schizophrenia
pp. 232-232(1)
Authors: Cooper S.J.; Butler A.; Tweed J.A.; Welch C.P.; Wighton A.J.; Appleby P.; Reynolds C.W.; Ruck A.

A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation
pp. 232-232(1)
Authors: Reeves K.R.; Swift R.H.; Harrigan E.P.

Health economic audit of long-term treatment with 'Seroquel' for patients with chronic schizophrenia
pp. 232-233(2)
Authors: Lee K.M.S.; Langham S.J.; Graves N.; Hellewell J.S.E.; Drummond M.F.

Compliance in schizophrenia
pp. 233-233(1)
Authors: Novak-Grubic V.; Tavcar R.

Risperidone augmentation of clozapin and olanzapine for refractory schizophrenia
pp. 233-233(1)
Authors: Mantonakis I.; Kattan K.; Zervas I.M.

Impact of neuroleptic medication on cognitive functioning in schizophrenia: Review of recent literature
pp. 234-234(1)
Author: Loftus J.B.

Effects of antipsychotic treatment on dopa decarboxylase activity in schizophrenia: A positron emission tomography study with [¹⁸F]fluorodopa
pp. 234-234(1)
Authors: Grinder G.; Davids E.; Heydari N.; Benz P.; Schlosser1 R.; Andreas J.; Stoeter P.; Wong D.F.; Gjedde A.

5-year follow-up of first episode schizophrenia: Progressive changes in cognition, neurological signs and brain structure
pp. 234-234(1)
Authors: Hemmingsen R.; Madsen A.; Karle A.; Holm A.-M.; Vorstrup S.; Rubin P.

Dopamine D4-like receptors in untreated schizophrenic patients demonstrated with PET and ¹¹C-SDZ GLC 756
pp. 235-235(1)
Authors: Klimke A.; Boy C.; Eickhoff M.; Herzog H.; Holschbach M.; Muhlensiepen H.; Weckesser M.; Rota Kops E.; Sonnenberg F.; Gaebel W.; Markstein R.; Stocklin G.; Coenen H.H.; Muller-Gartner H.W.

Subjective attitude to pharmacotherapy, knowledge about medication and compliance in the schizophrenic inpatients
pp. 235-235(1)
Authors: Szafranski T.; Waszkiewicz-Bialek E.; Kunicka A.

Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol
pp. 235-235(1)
Authors: Johnstone B.M.; Obenchain R.L.; Edgell E.T.; Croghan T.W.; Tunis S.L.; Kniesner T.J.

A cost effectiveness clinical decision analysis for schizophrenia: Results across four countries
pp. 236-236(1)
Authors: Edgell E.T.; Palmer C.S.; Revicki D.A.; Hamilton S.H.; Genduso L.A.; Daoud N.; Haley J.C.; Pitzer C.A.; Arffa A.; Sacristan J.A.; Mckendrick J.; Quik R.F.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial
pp. 236-236(1)
Authors: Hamilton S.H.; Edgell E.T.; Revicki D.A.; Genduso L.A.; Tollefson G.

Sertindole in clinical practice
pp. 236-236(1)
Authors: Pezawas L.; Quiner S.; Tauscher J.; Kuefferle B.; Barnas C.; Wolf R.; Kasper S.

Changes in the character of seizures induced by ehectrostimuiaticn of amygdaia in cats after treatment with choiinotropic drugs
pp. 237-237(1)
Authors: Tkachenko B.I.; Losev N.A.; Shalkovskaya L.N.

Choilnergic mechanisms in epileptogenic seizures development
pp. 237-237(1)
Authors: Sapronov N.S.; Losev N.A.

Cataleptic like immobility induced by nitric-synthase inhibitor: Pharmacological analysis
pp. 237-238(2)
Authors: Kostowskilz W.; Krzasci P.

The role of cortical NMDA receptors in the neuroleptic action
pp. 238-238(1)
Authors: Ossowska K.; Pietraszek M.; Wardas J.; Dziedzicka-Wasylewska M.; Nowak G.; Bajkowska M.; Wolfart S.

Comparison of the subjective response to typical neuroleptics, tisperidone and olazapine in schizophrenia
pp. 238-238(1)
Authors: Hormaechea J.A.; Garcia Cabeza I.; Sanz M.; Arango C.; Gonzalez de Chavez M.

Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder
pp. 238-238(1)
Author: Brecher M.

Effects of risperidone on affective symptoms in patients with schizophrenia
pp. 238-239(2)
Authors: Peuskens J.; De Smed C.; Lemmen P.; Van Baele B.

The population pharmacokinetics of intramuscular ziprasidone in healthy and schizophrenic subjects
pp. 239-239(1)
Authors: Tensfeld T.; Miceli J.; Kuye O.; Reeves K.; Swift R.; Harrigan E.

Validation of the behavioural activity rating scale (BARS): A novel measure of activity in agitated patients
pp. 239-239(1)
Authors: Swift R.H.; Harrigan E.P.; Cappelleri J.; Kramer D.; Chandler L.P.

Acute and subchronic effects of pimozide on isolation-induced aggression in male mice
pp. 239-240(2)
Authors: Velasco R.; Navarro J.F.; Manzaneque J.M.; Cavas M.; Pedraza C.

Behavioural analysis of the spatial learning deficit induced by dizocilpine (MK-801)
pp. 240-240(1)
Authors: Ahlander M.U.; Misane I.; Schott P.A.; Ogren S.O.

Treating tardive dyskinesia with ONDANSETRON
pp. 240-240(1)
Authors: Sirota P.; Mosheva T.; Shabtay H.; Barak Y.; Berger M.; Korcyn A.

Differential alterations in enkephalin mRNA expression in rat brain after chronic treatment with zotepine, clozapins and haloperidol
pp. 240-241(2)
Authors: Marksteiner J.; Mayr A.; Fleischhacker W.W.; Needham P.L.; Kilpatrick I.C.

Zotepine elevates dopamine in the frontal cortex of freely-moving rats measured by [n vivo microdialysis
pp. 241-241(1)
Authors: Rowley H.L.; Kilpatrick I.C.; Needham P.L.; Heal D.J.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers
pp. 241-242(2)
Authors: Brunner F.; Bhargava V.; Howard D.; Offord S.J.

A one-year study with determination of levels of clozapine in plasma of treatment-refractory schizophrenic patients
pp. 242-242(1)
Authors: De Ronchi D.; Baldini Rossi N.; Viscanti G.; Raggit M.A.; Michetti R.; Gentile D.; Bugamellit F.; Volterra V.

Clozapine and other atypical neuroleptics enhance histamine neuron activity: Evidence for serotonin implication
pp. 242-242(1)
Authors: Morisset S.; Sahm U.G.; Traiffort E.; Tardivel-Lacombe J.; Arrang J.M.; Schwartz J.C.

Immunophenotypic study of peripheral blood mononuclear cells in schizophrenic patients
pp. 242-243(2)
Authors: Theodoropouloul S.; Baxevanis C.N.; Spanakos G.; Papadopoulos N.G.; Economou M.; Papamichail M.; Stefanis C.

Plasma sex hormone levels in male schizophrenic patients in drug-free state or on treatment with neuroleptics, and after six weeks treatment with clozapine
pp. 243-243(1)
Authors: Hatzimanolis J.; Lykouras L.; Markianos M.

Correlation of brain dope decarboxylase activity and plasma homovanililc acid concentrations in schizophrenic patients before and under neuroleptic treatment
pp. 243-243(1)
Authors: Davids E.; Heydari N.; Harttert S.; Benz P.; Hierrtke C.; Griinder G.

Active [3H]-dopamine uptake displayed by native lymphocyte suspensions is mainly due to contaminating platelets
pp. 243-244(2)
Authors: Krieger K.; Klimke A.; Henning U.

Oxidative energy metabolism in peripheral blood lymphocytes of schizophrenic patients
pp. 244-244(1)
Authors: Tosca P.; Curti D.; Rognoni F.; Di Paolo E.; Zerbit F.

Concentration and microheterogeneity glycophorms of haptoglobin and transferrin in schizophrenia
pp. 244-244(1)
Authors: Sluzewska A.; Rybakowski J.; Sobieska M.

Attentional vulnerability indicators in patients with schizophrenia and their siblings
pp. 245-245(1)
Authors: d'Amato T.; Saoud M.; Dalery J.

Early amygdala or ventral hippocampal lesions affect locomotor and exploratory behaviours later in life: An animal model of neurodevelopmental disorders
pp. 245-245(1)
Authors: Daenen E.W.M.; Wolterink G.; Gerrits M.A.F.M.; Van Ree J.M.

Our experiences with neuroleptic therapy in treatment of the physical development problems at children of the age until seven years
pp. 245-246(2)
Author: Kaeva-Pejkovska M.

Amisulpride - Long-term safety
pp. 246-246(1)
Authors: Colonna L.; Tuganski S.; Dondey-Nouve L.

Non-specific autoantibodies in schizophrenic and depressive patients
pp. 246-246(1)
Authors: Wojtanowska M.; Rybakowski J.

In vivo evidence of central 5-HT_1A agonist activity of the novel antipsychotic ziprasidone
pp. 246-247(2)
Authors: Rollema H.; Sprouse J.S.; Lu Y.; Reynolds L.S.; Braselton J.P.; Zom S.H.

Subjective experience of patients on olanzapine in comparison to other antipsychotics
pp. 247-247(1)
Authors: Tuynman-Qua H.G.; de Roos V.; Duivenvoorden H.J.; van Meer C.R.

The atypical antipsychotic drugs, clozapine and zotepine differentially after neurotensin binding in rat brain when compared to haloperidol
pp. 247-247(1)
Authors: Holtom P.E.; Bennett G.W.; Needham P.L.; Aspley S.

Patients' satisfaction and acceptability of long-term treatment with 'Seroquel': Results of an international study
pp. 248-248(1)
Authors: Hellewell J.S.E.; Kalali A.H.; Langham S.L.; McKellar J.

Antipsychotic tolerability: The attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy
pp. 248-248(1)
Authors: Hellewell J.S.E.; Cantillon M.

Recognition memory of fictional narratives in schizophrenia
pp. 248-249(2)
Authors: Amado-Boccara I.; Denhiere G.; Bourdel M.C.; Olie J.P.; Poider M.F.; Loo H.

Attentional disorders - Working memory and schizophrenia - Comparison of treated and non treated patients
pp. 249-249(1)
Authors: Amado-Boccara I.; Daban C.; Willard-Schroeder D.; Krebs M.O.; Bourdel M.C.; Poirier M.F.

Differential actions of clozapine and the new antipsychotic agents
pp. 249-249(1)
Authors: Moore N.A.; Rees G.; Tree B.; Ward R.

Visualisation of dopamine-2 receptor blockade in psychotic patients treated with zotepine
pp. 249-250(2)
Authors: Barnas C.; Tauscher J.; Willeit M.; Kufferle B.; Krenn P.; Quiner S.; Asenbaum S.; Brucke T.; Rao M.L.; Kasper S.

Long-term treatment of schizophrenia - Focus on cognitive functions
pp. 250-250(1)
Authors: Vavrusova L.; Konikova M.; Forgacova L.; Zacharova Z.; Balentova E.

Functional role of brain dopamine D3 receptors in the rat
pp. 250-250(1)
Authors: de Beaurepaire R.; Barik S.

³H-spiperone binds with high affinity to a non-dopaminergic site on human B-lymphocytes, EBV transformed lymphoblasts and macrophages
pp. 250-251(2)
Authors: Henning U.; Krieger K.; Klimke A.

Saccadic eye movements in schizophrenic patients: The influence of neuroleptic treatment
pp. 251-251(1)
Authors: Krebs M.O.; Gut A.; Amado I.; Levy D.; Bourdel M.C.; Willard D.; Berthoz A.; Olie J.P.; Poirier M.F.

The effect of treatment with risperidone vs phenothiazine neuroieptics on eye tracking of schizophrenic patients during two fixation tasks
pp. 251-251(1)
Authors: Rybakowski J.K.; Borkowska A.; DroZdz W.; Araszkiewicz A.; Kucma A.

Creatine kinase levels in adolescents at early acute psychosis
pp. 251-252(2)
Authors: Manor I.; Hermesh H.; Stein D.; Shechtman T.; Benjamini Y.; Munitz H.; Weizmant A.

Twenty-four hour actigraphic monitoring in schizophrenic patients with acute neuroleptic-induced akathisia
pp. 252-252(1)
Authors: Poyurovsky M.; Nave R.; Tzischinsky R.O.; Schneidman M.; Lavie P.; Weizman A.; Barnes T.R.E.

Treatment of the symptoms of schizophrenia: A meta-analysis comparing risperidone with other antipsychotics
pp. 252-252(1)
Authors: Lemmens P.; De Smedt G.; Van Baelen B.

LU 111995, a dopamine D4 AND 5-hydroxytryptemine 2A antagonist: Pharmacological characterisation and first clinical experience
pp. 252-253(2)
Authors: Gross G.; Bailey P.; Bialojant S.; Garcia-Ladonat F.J.; Geyer M.; Greger G.; Luthringer R.; Macher J.-P.; Needham P.; Rendenbach-Muller B.; Steiner G.; Unger L.; Teschendorf H.-J.; Traut M.; Wicket K.

Neuropsychologlcal performances of chronic schizophrenic patients after one year exposure to risperldone compared to conventional neuroleptics
pp. 253-253(1)
Authors: Pourcher E.; Bouchard R.H.; Merette C.; Vallieres C.; Cohen H.

One-year follow-up of schizophrenic patients treated with Risperidone or classical neuroleptics: a prospective, randomized, multicentered open-study
pp. 253-253(1)
Authors: Bouchard R.H.; Pourcher E.; Merette C.; Demers M.F.; Villeneuve J.; Roy M.A.; Gauthier Y.; Cliche D.; Labelle A.; Maziade M.

Identifying symptom subtypes in obsessive-compulsive disorder: A factor analytic study
pp. 254-254(1)
Authors: Treuer T.; Nemeth A.; Vandlik E.; Vitrai J.; Furedi J.

Suicidal ideation and comorbidity in patients with the DSM-IV panic disorder width agoraphobia
pp. 254-254(1)
Authors: Stareevic V.; Bogojevic G.

Effects of severe personality disturbance on the outcome of intensive, integrative treatment of panic disorder with agoraphobia
pp. 254-255(2)
Authors: Starcevic V.; Latas M.; Trajkovic G.; Bogojevic G.

Impaired conditional discrimination in panic disorder patients
pp. 255-255(1)
Authors: Maierhofer D.; Dantendorfer K.; Anderer P.; Katschnig H.

Efficacy of paroxetine in social phobia - A single-center double-blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20-50 mg or placebo for 3 months
pp. 255-255(1)
Author: Allgulander C.

Differential pharmacotherapy in chronic generalized anxiety disorder
pp. 255-256(2)
Authors: Wurttunann C.; Kheser E.; Lehmann E.

Side effects of fluspirilene and their impact on clinical outcome in pharmacotherapy of generalized anxiety disorder
pp. 256-256(1)
Authors: Wurthmann C.; Klieser E.; Lehmann E.

Benzodiazepine audit in primary care
pp. 256-257(2)
Authors: De las Cuevas C.; De la Fuente J.A.; Sanz E.J.

Early response to sertraline as a predictor of 12-week outcome in panic disorder
pp. 257-257(1)
Authors: Pollack M.; Rapaport M.; Clary C.; Wolkow R.; Mardekian J.; Otto M.; Nierenberg A.

Double-blind, placebo-controlled study of once daily venlafaxine XR In outpatients with generalized anxiety disorder
pp. 257-257(1)
Authors: Haskins J.T.; Aguiar L.; Pallay A.; Rudolph R.

Pindolol does not augment the panicolytic effects of fluvoxamine in panic disorder patients
pp. 257-258(2)
Authors: van Vhet I.M.; Westenberg H.G.M.; den Boer J.A.

Clinical effects of venlafaxine in social phobia
pp. 258-258(1)
Authors: van Vliet I.M.; Westenberg H.G.M.; van Megen H.J.G.M.

Do anxious patients referred to psychiatrists differ from those recruited through newspaper advertising?
pp. 258-258(1)
Authors: Boulenger J.P.; McCusker J.; Ouellet N.; Miller J.M.; Bellavance F.

Psychometric properties of the severity of dependence scale in the benzodiazepine users
pp. 259-259(1)
Authors: De las Cuevas C.; Cabrera C.; Cabrera E.; Sanz E.J.; De la Fuente J.A.

Assessing social phobia. The Spanish validation of the sheehan disability scales
pp. 259-259(1)
Authors: Gonzalez M.P.; Bobes J.; Garcia M.; Badia X.; Luque A.; Dal-Re R.

Assessing social phobia. The Spanish validation of the ''gold standard'' clinical scales: The LSAS and the SADS
pp. 259-260(2)
Authors: Gonzalez M.P.; Bobest J.; Garcia M.; Badia X.; Luque A.; Dal-Re R.

Power spectrum analysis of heart rate variability: A window to the interbalance of the autonomic system in panic disorder and posttraumatic stress disorder patients
pp. 260-260(1)
Authors: Cohen H.; Matar M.A.; Kaplan Z.; Miodownik H.; Kotler M.

A double-blind comparison of fluvoxamine and clomipramine in OCD
pp. 260-261(2)
Author: Rouillon F.

Double-blind flexible dose multicenter study of sertraline and placebo in outpatients with post-traumatic stress disorder
pp. 261-261(1)
Authors: Baker D.; Brady K.; Goldstein S.; Farfel G.

Long-term treatment of obsessive-compulsive disorder following acute response: A comparison of fluoxetine versus placebo
pp. 261-261(1)
Authors: Romano S.; Goodmanz W.; Tamura R.; Sundell K.

The temperament and character inventory (TCI) as a screening instrument for personality disorders in anxiety disorders
pp. 261-262(2)
Authors: Sangorrin J.; Perez G.; Gutierrez F.; Torrens M.; Bulbena A.; Martin-Santos R.

Intensive behavior therapy camp for patients with OCD
pp. 262-262(1)
Authors: Nemeth A.; Lukacs E.; Morotz K.; Molnar K.

Epidemiology of OCD: A hungarian sample
pp. 262-262(1)
Authors: Nemeth A.; Szadoczky E.; Trcuer T.; Vandlik E.; Papp Z.

Paroxetine in the treatment of social anxiety disorder (social phobia): An overview
pp. 262-262(1)
Authors: Baldwin D.S.; Pitts N.; Gergell I.; Traverst J.

One year test-netest study of joint hypermobility syndrome in panic out-patients
pp. 263-263(1)
Authors: Martin-Santos R.; Bulbena A.; Gago J.; Cabre M.; Masip C.; Serrano D.

Panic attacks as a manifestation of a seizure disorder in children
pp. 263-263(1)
Authors: Leor A.; Brand N.

Sertrallne for obsessive-compulsive disorder without depression: A multicenter, open-lable study
pp. 263-263(1)
Authors: Sungur M.; Taneli B.; Yazgan Y.; Tunca Z.; Alptekin K.; Karaaslan F.

Influence of vigabatrin on exploratory behaviour in rats upon diazepam withdrawal
pp. 263-264(2)
Author: Sherif F.M.

Citalopram versus clomipramine in double-blind therapy of obsessive-compulsive disorder
pp. 264-264(1)
Authors: Pidrman V.; Tuna I.

Platelet ³H-Paroxetine binding in OCD spectrum disorders
pp. 264-264(1)
Authors: Marazziti D.; Rossi A.; Baroni S.; Palego L.; Masala I.; Giannaccini G.; Lucacchini A.; Cassano G.B.

Paroxetine, domiprarrdne and cognitive therapy in the treatment of panic d1sorder
pp. 264-264(1)
Author: Bakker A.

Increased psychological responses and divergent neuroendoerins responses to ipsapirone and m-CPP in patients with panic disorder
pp. 265-265(1)
Authors: Broocks A.; George A.; Bartmann U.; Bandelow B.; Hajak G.; Ruther E.

Venlafaxine XR (V XR) is an efficacious short-and long-term treatment for generalized anxiety disorder (GAD)
pp. 265-265(1)
Authors: Haskins J.T.; Rudolph R.; Aguiar L.; Entsuah R.; Salinas E.

The mirror chamber test for testing anxiolytics: Is there a mirror induced stimulation?
pp. 265-265(1)
Author: Lamberty Y.

Intracerebral perfusion of buspirone in dorsal raphe nucleus: Behavioural consequences on anxiolytic state measured in open-field and elevated plus maze, and on locomotor activity in mice
pp. 266-266(1)
Authors: Coubard S.; Froger N.; Belzung C.; Barone P.

Nefazodone in social phobia: A pilot study
pp. 266-266(1)
Authors: Van Ameringen M.; Mancini C.; Oakman J.M.

Development of major depression in panic disorder: Is it related to the type of medication treatment and short term response?
pp. 266-266(1)
Authors: Arriaga F.; Cavaglia F.; Abreu M.; Matos-Pires A.; Lara E.

A general population survey on patterns of benzodiazepine use, abuse and dependence in Lebanon
pp. 266-267(2)
Authors: Naja W.J.; Baddoura R.; Haddad R.S.; Pelissolo A.; Baddoura C.

The influence of a new cholecystokinin analogue CCK-4 on ³H-diazepam binding in the midbrain of rats with different anxiety levels
pp. 267-267(1)
Authors: Anokhina I.; Proskuryakova T.; Petrichenko O.; Pankratova N.; Bespalova Z.

Combination of inositol and serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder
pp. 267-267(1)
Authors: Fux M.; Nemetz B.; Belmaker R.H.

Fluoxetine, citalopram and imipramine in the treatment of panic disorder: A double blind clinical study
pp. 267-268(2)
Authors: Amore M.; Magnani K.; Cerisoli M.; Casagrande C.

The panic and agoraphobia scale (P & A): An instrument sensitive to differences between treatment modalities
pp. 268-268(1)
Authors: Bandelow B.; Broocks A.; Meyer T.; Rather E.

Millon multiaxial personality patterns differentiate depressed and anxious outpatients
pp. 268-268(1)
Authors: Freeman A.M.; Kablinger A.S.; Brannon G.E.; Rush J.A.; Roggero B.

The nature of benzodiazepine low-dosage dependency
pp. 268-268(1)
Authors: Linden M.; Bar T.

Double-blind, placebo-Icomparator-controlled study of once daily veniafaxine XR (V-XR) and buspirons (Bsp) in outpatients with generalized anxiety disorder (GAD)
pp. 269-269(1)
Authors: Haskins J.T.; Rudolph R.; Aguiar L.; Entsuah R.

Test therapy in pharmacological treatment of generalized anxiety disorder
pp. 269-269(1)
Authors: Wurthmann C.; Klieser E.; Lehmann E.

The role of brain GABAergic and serotonergic systems in habituation of rat motor activity
pp. 269-270(2)
Authors: Siemigkowski M.; Piaznik A.; Czionkowska A.; Bidzinski A.; Sienkiewicz-Jarosz H.

Increased panic-like anxiety induced in rats by the 5-HT1A receptor agonist flesinoxan
pp. 270-270(1)
Authors: Jenck F.; Martin J.R.; Moreau J.L.

Drugs acting on adenosine receptors and anxiety in the mouse
pp. 270-270(1)
Authors: El Yacoubi M.; Costentin J.; Vaugeois J.-M.

Alprazolam and lorazepam: Differential tolerance development to the adverse memory effects in the elderly
pp. 270-271(2)
Authors: Pomaral N.; Shao B.; Deptula D.; Greenblatt D.J.

Genetic and sex differences in anxiety responses and benzodiazepine treatment in house mice
pp. 271-271(1)
Authors: Palanza P.; Ferrari P.F.; Parmigiani S.

Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years therapy using donepezil
pp. 271-271(1)
Author: Stewart A.

Selegiline in the treatment of mild and moderate stages of Alzheimer disease
pp. 271-272(2)
Authors: Gheorghe M.D.; Grigorescu G.

Apolipoprotein E4 allele frequency in vascular dementia in the Hungarian population
pp. 272-272(1)
Authors: Juhasz A.; Kalman J.; Rimanoczy A.; Csaszar A.; Kankal A.; Jankal Z.; Rasko I.

Aniracetam treatment (low dosage) for the patients with emotional disturbance due to cerebral infarctions
pp. 272-273(2)
Authors: Kobayakawa M.; Mori K.; Nagao M.; Hirayama S.; Harada Y.; Kashiwagi K.; Irisawa T.; Nagao K.

Follow-up study of risperidone in the treatment of patients with dementia: Interim results on tardive dyskinesia and dyskinesia severity
pp. 273-273(1)
Author: Brecher M.

Bright light therapy and melatonin in motor restlessness in dementia
pp. 273-273(1)
Authors: Haffmans P.M.J.; Lucius S.A.Y.; Sival R.C.

Long-tern safety and efficacy of risperidone in the treatment of behavioral disturbances in elderly patients with dementia
pp. 273-273(1)
Authors: De Deyn P.P.; De Smedt G.

Donepezil improves cognition and global function in Alzheimer's disease: Results from us and multinational phase III clinical trials
pp. 274-274(1)
Authors: Petit H.; Doody R.S.; Pratt R.D.

Follow-up investigation of patients with mild Alzheimer disease, vascular and mixed dementia
pp. 274-274(1)
Authors: Jarikov G.A.; Rochtchina I.F.; Savvateeva N.Y.

Modification of clinical effects and tolerability of cholinergic therapy by preceding cerebrolysin treatment in Alzheimer's disease
pp. 274-275(2)
Authors: Gavrilova S.; Kolykhalov I.; Selezneva N.; Jarikov G.

Olanaapin for psychosis in patients with Parkinson's disease with and without dementia
pp. 275-275(1)
Authors: Aarsland D.; Larsen J.P.; Lim N.G.; Tandberg E.

Psychiatric disorders in a general hospital: HIV patients compared to non-HIV patients
pp. 275-275(1)
Author: Becker U.

Effects of calcium channel blockers, MK-801 and nimodipine on the Na,K-ATPase activity in rats exposed to hypoxia and cerebral ischemia
pp. 275-276(2)
Authors: Mrsic J.; Maysinger D.; Zupan G.; Simonic A.

T-cell tumor necrosis factor- binding in Alzheimer's disease: Effect of donepezil
pp. 276-276(1)
Authors: Bongioanni P.; Boccardi B.; Pellegrino D.; Baldini C.; Gabrielli L.; Ferroni L.; Rossi B.

Risk factors of Alzheimer's disease (A case-control study)
pp. 276-276(1)
Author: Bratsoun A.L.

Striatal neurotensin increases pallidal glutamate and GARA release via a pallidai-subthalamic nucleus loop
pp. 276-277(2)
Authors: Ferraro L.; O'Connor W.T.; Antonelli T.; Fuxe K.; Soubrie P.; Tanganelli S.

Phannacotherapy of elderly patients with cognitive deficiency and/or depression
pp. 277-277(1)
Authors: Munjiza M.; Mitrovic S.; Ljubomirovic N.

The quantitative EEG in early and differential diagnosis of mild dementia of different genesis
pp. 277-278(2)
Authors: Iznak A.F.; Kolykhalov I.V.; Zhygulskaya S.E.; Vasilieva A.G.; Selezneva A.G.; Selezneva N.D.

Neuropsychologic method in diagnosis of mild dementia in elderly and senile patients
pp. 278-278(1)
Author: Rochtchina I.

Memory complaints in elderly GP-patients
pp. 278-278(1)
Author: Milchailova M.

Depressive disorders and their role as possible predictors of cognitive pharmacotherapy effects in Alzheimer's disease
pp. 278-279(2)
Authors: Selezneva N.; Kolykhalov I.; Jarikov G.; Bratsoun A.; Gavrilova S.

Immune activation in patients with Alzheimer's disease
pp. 279-279(1)
Authors: Leblhuber F.; Walli J.; Tilz G.P.; Widner B.; Fuchs D.

CGP 36742 prevent PTZ-kindling-provoked amnesia in rats
pp. 279-279(1)
Authors: Genkova-Papazova M.; Petkova B.; Tomova E.; Lazarova-Bakarova M.

Cognitive, behavioural and neuroendocrine effects of cholecystokinin-4 infusion in healthy volunteers
pp. 280-280(1)
Authors: Shlik J.; Koszycki D.; Bradwejnz J.

Serum cholinesterase and red blood cell acetylchollnesterase activity in patients with Alzheimer's disease and the effect of aluminofluoride complexes
pp. 280-280(1)
Authors: Strunecki A.; Eminger M.; Ripova D.; Jirak R.

The influence of verapamil on cognitive functions in experimental model of Alzheimer's disease in rats
pp. 280-281(2)
Authors: Ivkovic M.; Jasovic-Gasic M.; Paunovic V.

Role of the shaker-like Kv1.1 potassium channel in mouse cognitive processes
pp. 281-281(1)
Authors: Ghelardini C.; Galeotti N.; Bartolini A.

Therapy perspectives in alcohol dependence
pp. 281-281(1)
Author: Boisteanu P.

Calcium channel antagonists reduce affective disorders in abstinent alcoholic patients
pp. 281-282(2)
Authors: Krupitsky E.; Burakov A.; Vostrikov V.; Kopchak A.; Romanova T.; Grinenko A.

Alcoholism treatment with antidepressant mianserin
pp. 282-282(1)
Author: Ivanets N.

Alcohol abuse and deviant social behaviour
pp. 282-282(1)
Authors: Liappas J.; Peppas E.; Pomini V.; Papavasihou P.; Christodoulou G.N.

Comparison of criminality between drug and alcohol users: Preliminary report
pp. 282-282(1)
Authors: Liappas J.; Peppas E.; Paparrigopoulos T.; Pomini V.; Christodoulou G.N.

The role of hyperbaric oxygenation in treatment of alcohol abuse and drug addiction
pp. 282-283(2)
Authors: Epifanova N.; Romasenko M.; Koukchina A.; Epifanov I.

Cue exposure: A non-pharmacological intervention for the reduction of drug craving: A pilot study
pp. 283-283(1)
Authors: Franken I.H.A.; Hendriks V.M.

Benzodiazepines' consumption in the contexts of poly-substance abuse and of impulse dyscontrol
pp. 283-284(2)
Authors: Levarta E.; Forza G.; Da Ros D.; Schifano F.

Naltrexone and/or sertraline in outpatients with alcoholism and depression
pp. 284-284(1)
Authors: Mason B.J.; Salvato F.R.; Williams L.D.; Cutler R.B.

The prescribed medication of hospitalized dualdiagnosis patients: A need for specific pharmacotherapy-strategies
pp. 284-284(1)
Authors: Bachmann K.M.; Moggi F.; Koltzsch K.; Brodbeck J.; Hirsbrunner H.P.

Interactions between psychotropes and methadone substitution in opioid abusers
pp. 284-284(1)
Authors: Paris P.C.; Popa C.

Rapid psychiatric treatment of detoxification from opiates
pp. 285-285(1)
Authors: Conte G.L.; Taranto C.; Camardese G.; Buonanno A.; De Risio S.

Quality of life, psychopathological status and drug use in a methadone maintenance treatment in Spain
pp. 285-285(1)
Authors: Femandez-Miranda J.J.; Gonzalez M.P.; Saiz P.A.; Gutierrez E.; Bobes J.

Ecstasy consumption in opiate addicts: Personality disorders and severity of addiction
pp. 285-285(1)
Authors: Gutierrez E.; Saiz P.A.; Fernandez J.J.; Gonzilez M.P.; Bobes J.

Carbamaaepin in the treatment of the alcohol withdrawal syndrome
pp. 285-286(2)
Authors: Lazarova V.; Jakovcevska-Kujundiiska M.; Filovska V.

Efficacy of finlepsin-retard by alcoholism with comorbld brain impairment
pp. 286-286(1)
Authors: Semke V.; Bokhan N.

Impact of methadone maintenance treatment in the clinical profile of patients admitted at a detoxification unit
pp. 286-286(1)
Authors: Alda J.A.; Torrens M.; Martin-Santos R.; Castillo C.; Tato J.; San L.

Methadone and buprenorphine in maintenance therapy for opiod dependence
pp. 286-287(2)
Authors: Eder H.; Fischer G.; Gombas W.; Jagsch R.; Haberler B.; Rossler B.; Kasper S.

Safety study of buprenorphine during pregnancy
pp. 287-287(1)
Authors: Fischer G.; Eder H.; Jagsch R.; Rossler B.; Langer M.

Magnesium sulphate IN. as an adjunct therapy in opiate detoxification
pp. 287-287(1)
Authors: Heiden A.; Frey R.; Presslich O.; Blasbichler T.; Frottier P.; Kasper S.

Comparative study of peculiarities of alcocholism and drug addiction for the aborigines of the North of Russia and individuals of European origin
pp. 287-287(1)
Author: Krivogornitsina E.A.

Carbamazepin in prevention of delirium tremens alcoholicum
pp. 288-288(1)
Authors: Vuckocic N.; Dickov A.; Misic-Pavkov G.; Dorosski M.; Bujsic G.

The temperament and character inventory (TCI) in patients with substance use disorders: Comparative study with community subjects
pp. 288-288(1)
Authors: Pelissolo A.; Gourion D.; Pezous A.-M.; Lepine J.-P.

Pharmacodynamiclpharmacokinetic relationship of propranoloi in alcoholic patients
pp. 288-288(1)
Author: Kahkonen S.

PK11.195 binding to peripheral granulocytes in detoxitled alcoholics
pp. 288-289(2)
Authors: Wodarz N.; Wiesbeck G.A.; Weijers H.G.; Boning J.

The effect of some calcium antagonists on phenobarbital withdrawal syndrome in rats
pp. 289-289(1)
Authors: Lazarova M.; Petkova B.; Delchev Y.; Zlatanova S.; Staneva-Stoycheva D.

Toxicological and psychological profile of MDMA (ecstasy) abusers and non-abusers in military conscripts
pp. 289-290(2)
Authors: Saiz P.A.; Gonzalez M.P.; Bousoiio M.; Bobes J.

Low-affinity NMDA receptor channel blockers, memantine and MRZ 2/579, modulate initiation of morphine intravenous self-administration in naive mice
pp. 290-290(1)
Authors: Bespalov A.Y.; Semenova S.G.; Danysz W.

Reinstatement of cocaine self-administration behavior by priming with cocaine injected into the nucleus accumbens septi in rats
pp. 290-290(1)
Authors: Bespalov A.Y.; Wolterink G.; van Ree J.M.

Caroverin, a calcium channel-blocking and antiglutamatergic agent, vs. diazepam in the treatment of alcohol withdrawal syndrome (ICD 10 F 10.3). A double-blind randomised study
pp. 290-291(2)
Authors: Geretsegger C.; Feldinger F.; Stelzig R.; Whitworth A.B.

Nerve growth factor - a serum marker for severe alcohol-dependence
pp. 291-291(1)
Authors: Jockers-Scherfibl M.C.; Kuhn S.; Ropke S.; Schmidt L.G.; Hellweg R.

The receptor mechanisms of oploid tolerance and dependence
pp. 291-291(1)
Authors: Furst S.; Hosztafi S.; Friedmann T.

Ethanol-reinforced behaviour in rats: effects of memantine
pp. 292-292(1)
Authors: Bienkowski P.; Piasecki J.; Koros E.; Dyr W.; Kostowski W.; Danysz W.

Serotonerglc alterations in the rat brain during ethanol withdrawal
pp. 292-292(1)
Authors: Uzbay I.T.; Usanmaz S.E.; Akarsu E.S.

The effects of the NMDA receptor antagonists on the rewarding properties of ethanol measured in the conditioned place preference paradigm in rats
pp. 292-293(2)
Authors: Biala G.; Kotlinska J.

ACPC, a partial agonist at strychnine-insensitive glycine receptors, has no effect on the discriminative stimuli of amphetamineand cocainea
pp. 293-293(1)
Authors: Papp M.; Filip M.; Przegalinski E.

The activating effects of cross-sex hormones on cognitive functioning: A study of short-term and long-term hormone effects in transsexuals
pp. 293-293(1)
Authors: Slabbekoom D.; van Goozen S.H.M.; Megens J.; Gooren L.J.G.; Cohen-Kettenis P.T.

Bipolar affective disorder II. The correlation between ERPs & CT findings
pp. 293-293(1)
Authors: Karaaslan M.F.; Ogu A.; Esl E.; Gonul A.S.; Turan T.; Arman F.

Bipolar affective disorder: I. The CT findings in various subgroups
pp. 294-294(1)
Authors: Karaaslan M.F.; Oguz A.; Ozcan N.; Basturk M.; Esel E.; Gonul A.S.

Comorbid mental pathology preceding the late life major depression
pp. 294-294(1)
Authors: Medvedey A.V.; Belova M.J.; Kolesnitshenko A.I.; Kurmishev A.N.; Tshebishev P.A.; Shishina T.F.

Zolpidem improves sleep in travelers following eastward transatlantic flight
pp. 294-295(2)
Authors: Jamieson A.; Zammit G.; Walsh J.; Maclntyre J.; Allard S.; RothSchechter B.

Determination of putative predictors of the number of non-rapid' eye movement sleep episodes in healthy men
pp. 295-295(1)
Authors: Preud'homme X.; Vanderzeypen F.; Dougherty J.; Lanquart J.-P.; Mendlewicz J.; Linkowski P.

Pathological gambling: An open-label study with fluoxetine
pp. 295-296(2)
Authors: de la Gandam J.J.; Sanz O.; Gilaberte I.

Visual cognitive deficits in patients with borderline personality disorder
pp. 296-296(1)
Authors: Gschwandtner U.; Rauchfleisch U.; Riecher-Rossler A.

Risperidone in the treatment of aggressive behaviour disorders in adolescents with mild mental retardation. A prospective, randomised, double-blind, placebo-controlled trial
pp. 296-296(1)
Authors: Buitelaar J.K.; van der Gaag R.-J.; Melman C.T.M.

Effect of blood collection tubes on tricyclic antidepressant blood levels
pp. 296-297(2)
Authors: Veen G.J.; Oostelbos M.C.J.M.; Toll P.J.M.M.; Loonen A.J.M.

Zaleplon decreases sleep latency in outpatients after 4 weeks of treatment
pp. 297-297(1)
Authors: Emilien G.; Salinas E.

Cerebral functional connectivity in psychiatric disorders
pp. 297-298(2)
Authors: Mallet L.; Falissard B.; Artiges E.; Martinot J.L.

Utilization of medical services in bipolar I disorder
pp. 298-298(1)
Authors: Stender M.; Bryant-Comstock L.; Phillips S.

The pharmacological treatment of violent patients: An open clinical study
pp. 298-298(1)
Authors: Amore M.; Zazzeri N.; D'Ambrosio S.; Ferrari G.

Adaptation and validation of the Spanish version of the changes in sexual functioning questionnaire (CSFQ): Methodology and results
pp. 298-299(2)
Authors: Bobes J.; Gonzalez P.; Sarasa P.; Banns S.; Salvat S.

Influence of age and gender on cortical 5-HT_2A receptor density in healthy subjects measured with SPECT and ¹²³I-5-I-R91150
pp. 299-299(1)
Authors: Baeken C.; D'haenen H.; Mertens J.; Terriere D.; Chavatte K.; Boumon R.; Flamen P.; Bossuyt A.

T-cell tumor necrosis factor- binding in myasthenia gravis
pp. 299-299(1)
Authors: Bongioanni P.; Ricciardi R.; Pellegrino D.; Boccardi B.; Baldini C.; Chisari C.

Hemispheric activation in children with ADHD
pp. 299-300(2)
Authors: Dabkowska M.; Borkowska A.; Rybakowskil J.; Araszkiewicz A.

Gastrin is related to personality traits as well as depression in female patients with somatoform disorders and population controls
pp. 300-300(1)
Authors: Malt E.A.; 01afsson S.; Lund A.; Aakvaag A.; Ursin H.

Neurotropic effects of intranasally administered peptide sedatin - A new structural analog of dermorphin
pp. 300-300(1)
Authors: Uranova M.G.; Latysheva N.V.; Yarova E.P.; Deigin V.I.; Kamensky A.A.

Psychotropic drug use in old age (results of the Berlin aging study)
pp. 300-300(1)
Authors: Linden M.; Bar T.

Olanzapine in Gilles de la Tourette Syndrome patients
pp. 301-301(1)
Authors: Stamenkovic M.; Schindler S.D.; Aschauer H.N.; Kasper S.

The use of cerebrolysin and magne B6 for the correction of adverse effects resulting from psychotropic therapy
pp. 301-301(1)
Authors: Panteleeva G.P.; Bondar V.V.; Rayushkin V.A.; Kaleda V.G.

Depressive symptoms and neurotransmitters in cerebrospinal fluid in hypothyroid patientsa
pp. 301-302(2)
Authors: Gunnarsson T.; Erikssonb M.; Sjobergb S.; Nordinc C.

Osteopenia in anorexia nervosa (AN): Markers of bone turnover show increased resorption and decreased formation
pp. 302-302(1)
Authors: Lennkh C.; Bailer U.; Stmad A.; Nagy C.; Wiesnagrotzki S.; de Zwaan M.; Kasper S.

Early short-term amitriptiline administration for prevention of postherpetic neuralgia
pp. 302-302(1)
Authors: Ser F.; Milovanovicz S.; Lazovici M.; Veljkovic M.

Psychopathological implications in course of spinal cord injuries and their pharmacological treatment
pp. 302-303(2)
Author: Piatkowska H.

The influence of progesterone to the convulsive activity of brain
pp. 303-303(1)
Authors: Geraibeily G.C.; Sultanov A.A.

Pharmacological characterization of 5-HT2C receptors in human brain
pp. 303-303(1)
Authors: Rossi A.; Marazziti D.; Zavaglia K.; Baroni S.; Masala I.; Giannaccini G.; Lucacchini A.; Cassano G.B.

Effects of acute tryptophan depletion on sleep in patients with obsessive-compulsive disorder, insomnia and healthy subjects
pp. 303-304(2)
Authors: Huwig-Poppe C.; Voderholzer U.; Homyak M.; Backhaus J.; Kiemen A.; Riemann D.; Hohagen F.

The genetic variant A of human alpha 1-acid glycoproteln limits the blood to brain transfer of drugs It binds - Pharmacological consequences
pp. 304-304(1)
Authors: Jolliet P.; Boukef M.F.; Duche J.C.; Simon N.; Tillement J.P.

Cerebral structural abnormalities as markers of liability to schizophrenia
pp. 304-304(1)
Authors: Orlova V.A.; Trubnikov V.I.; Savvateeva N.Y.; Odintsova S.A.

Agression and hostility in panic disorder and major depression: Correlations with serotonine parameters
pp. 304-305(2)
Authors: Timmerman L.; Fekkes D.; Pepplinkhuizen L.

A multicenter study on the efficacy and tolerability of levosulpiride in the treatment of somatoform disorders
pp. 305-305(1)
Authors: Altamural A.C.; Ermentini A.; Guaraldi G.P.; Invemizzit G.; Meduri M.

Stimulation of group 11 metabotropic glutamate receptors counteracts parkinsonian-like muscle rigidity
pp. 305-305(1)
Authors: Wolfarth S.; Koniecmy J.; Lorenc-Kocil E.; Ossowskal K.; Pilc A.

The perceived cost of newer antipsychotics may be unfounded: Predictions of a decision tree model
pp. 305-306(2)
Authors: Byrom W.D.; Kilpatrick A.T.; Garratt C.J.

Zotepine pharmacokinetics: Effect of dose
pp. 306-306(1)
Authors: Hind I.D.; Mangham J.E.; Wynne R.D.; Haddock R.E.

Correlations between multi-level characteristics of schizophrenia pathogenesis in families
pp. 306-306(1)
Authors: Savina T.D.; Orlova V.A.; Trubnikiv V.I.; Savvateeva N.Y.; Sherbakova N.P.

Aetiology of aseptic meningitis with special reference to tuberculous meinigitis
pp. 306-307(2)
Authors: Tohami S.A.; Darwish E.S.; Azmy W.M.; EI-Feky M.A.

Detection and cost analysis of adverse drug reaction in hospitalized patients with psychiatric disorders
pp. 307-307(1)
Authors: Tazarourte M.; Catteau J.; Fall A.; Bordet R.; Parquet P.-J.

Psychopathology in patients with primary fibromyalgia, with rheumatoid arthritis and subjects without pain
pp. 307-307(1)
Authors: Michelidakis K.; Myriokefalitakis J.; Vezyrogiou G.

Impulsivity, suicide risk, acts of violence, and platelet MAO activity in a forensic male population
pp. 307-307(1)
Authors: Botsis A.J.; Skondras M.; Markianos M.

Hypothalamic-pituitary-adrenocortical-system alterations in aging and depression: Contribution of vasopressin to underlying pathophysiology
pp. 308-308(1)
Authors: Hatzinger M.; Wotjak C.T.; Keck M.E.; Landgrafl R.; Hemmeter U.; Holsboer-Trachsler E.; Holsboerl F.; Neumann I.

The role of fluoxetine in the treatment of premenstrual dysphoric disorder
pp. 308-308(1)
Authors: Judge R.; Romano S.; Dillon J.

A health economic analysis of pharmacotherapy for major depressive disorder in Europe and the Americasa
pp. 308-309(2)
Authors: Arikian S.R.; Doyle J.J.

Sertraline efficacy in the treatment of premenstrual dysphoric disorder (PMDD)
pp. 309-309(1)
Authors: Castro R.R.; Montalban S.R.; Bisen J.R.D.; De la Torre Hemandez J.

Quality of life during antihypertensive therapy
pp. 309-309(1)
Authors: Akbtytk D.I.; Gokkurt E.

A double-blind carbamazepine-controlled efficacy and safety study of vaiproate in impulsivity and violence
pp. 309-309(1)
Authors: Mosca L.D.; Licciardo J.P.; Coppola J.L.

Membrane-protective effect of delta-sleep inducing peptide
pp. 309-310(2)
Authors: Bondarenko T.I.; Goroshinskaya I.A.; Mikhaleva I.I.; Shustanova T.A.

Reflex regulation of individual resistance to stress with ethanol by means of stimulation of gastric afferents
pp. 310-310(1)
Authors: Gmiro V.E.; Sapronov N.S.; Serdyukl S.E.

The use of citalopram in a multimodal approach to the therapy of bulimia nervosa
pp. 310-310(1)
Authors: Calandra C.; Gulino V.; Giuffrida A.; Inserra L.

OFQ knock-out mice: Behavioral phenotype seems to indicate homeostatic compensation of OFQ functional deficits
pp. 310-310(1)
Authors: Jenck F.; Borroni E.; Cesura A.M.; Alberati-Giani D.; Moreau J.L.; Pauly-Evers M.; Bluethmann H.; Koester A.

Comparing investigators' use of rating scales such as PANES in mufti-investigator studies of schizophrenia
pp. 310-311(2)
Authors: Channon E.; Butler A.

The brief psychiatric rating scale and the clinical global impressions scale for severity: A balanced view
pp. 311-311(1)
Authors: Cooper S.J.; Tweed J.A.; Butler A.; Wighton A.J.; Welch C.P.

Transcranial magnetic stimulation induces changes in coping strategies and attenuates the activity of the hypothalamic-pituitary-adrenocortical system in rats
pp. 311-311(1)
Authors: Keck M.E.; Engelmann M.; Ebner K.; Post A.; Henniger M.; Neumann I.D.; Landgraf R.; Holsboer E.

Effects of the D3 preferring dopamine agonist pramipexoie on sleep and waking, locomotor activity and striatal dopamine release in rats
pp. 312-312(1)
Authors: Monti J.M.; Lagos P.; Scorza C.; Jantos H.; Reyes-Parada M.; Silveira R.; Ponzoni A.

Long-term treatment of bulimia nervosa following acute response: A comparison of fluoxetine versus placebo
pp. 312-312(1)
Authors: Romano S.; Tamura R.; Sundell K.

The 5-HT_1A and 5-HT_2A receptor affinity and functional profile of now N-[3-(4-aryl-1-piperazinyl) propyl] derivatives of some benzolactams
pp. 312-313(2)
Authors: Chojnacka-Wojcik E.; Duszynska B.; Klodzinska A.; Tatarczynska E.

Structural changes in rat brains after electroconvulsive treatment (ECT) and transcranial magnetic stimulation (TMS)
pp. 313-313(1)
Authors: Zyss T.; Adamck D.; Mamcarz J.

Neuroendocrinergic and biochemical indicators of aggressive behaviour and violence
pp. 313-313(1)
Authors: Cetin M.; Cilden S.; Basoglu C.; Ebrinc S.; Ozcubukcuoglu A.; Evren C.; Burkovik Y.

Prenatal stress induces long-term sleep alterations in adult rats: Implication for depression
pp. 314-314(1)
Authors: Dugovic C.; Maccari S.; Clincke G.; Van Reeth O.

Effects of interaction between gammahydroxybutyrate and tiapride on agonistic encounters in male mice
pp. 314-314(1)
Authors: Pedraza C.; Navarro J.F.; Martin-opez M.; Cavas M.

Coadministration of gammahydroxybutyrate and N-nitro-L-arginine: Effects on catalepsy of male mice
pp. 314-315(2)
Authors: Navarro J.F.; Pedraza C.; Martin-Lopez M.; Maldonado E.

Coadministration of N-nitro-L-arginine and tiapride: effects on catalepsy of male mice
pp. 315-315(1)
Authors: Cavas M.; Navarro J.F.; Martin-Lopez M.; Manzaneque J.M.; Vera F.

Cerebrospinal fluid levels of monoamine compounds and cholecystokinin peptides after exposure to standardized barometric pressure
pp. 315-315(1)
Authors: Gunnarsson T.; Eklundh T.; Nordin C.; Ornhagen H.

Cultured neuroepithelial cells from human olfactory biopsies as a model system for neuropsychiatric disorders
pp. 315-316(2)
Authors: Rujescu D.; Rasp G.; Gaese F.; Grunze H.; Padberg E.; Moeller H.-J.; Stamm S.

Non organ-specific autoantibodies in patients with psychiatric disorders
pp. 316-316(1)
Authors: Placidi G.P.A.; Boldrini M.; Caponi L.; Biagi M.; Marazziti D.; Dell'Osso L.; Cassano G.B.

Rorschach markers in offspring of manic-depressive patients
pp. 316-316(1)
Authors: Osher Y.; Mandel B.; Kampf-Sherf O.; Belmaker R.H.

Characterization of the discriminative stimulus effects of the novel neuroprotectant BAY x 3702 in the rat
pp. 317-317(1)
Authors: De Vry J.; Jentzsch K.R.

The prototype rapid-rate magnetic stimulator for prolonged TMS - developing of core coil with water cooling system
pp. 317-317(1)
Authors: Zyss T.; Domino A.; Senkowski J.; Gierlik S.; Gierlik D.

Electroshock therapy (ECT) versus transcranial magnetic stimulation (TMS): modeling of current flow in 3-D head structure
pp. 317-317(1)
Authors: Zyss T.; Krawczyk A.; Drzymala P.; Starzynski J.

No evidence of epileptogenic potential of prolonged rapid-rate transcranial magnetic stimulation in rats
pp. 318-318(1)
Author: Zyss T.

Efficacy and safety of Zopiclone treatment in outpatients with chronic insomnia
pp. 318-318(1)
Authors: Zyss T.; Szymusik A.

Author index
pp. 319-329(11)